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Dear Readers,
Peripheral artery disease (PAD) is a common disease, though not very well known and often diagnosed on a very late 
stage, causing not only typical complications such as intermittent claudication, critical limb ischemia or amputations, 
but also to cardiovascular mortality. The risk of cardiovascular death can be even 11 times higher in patients with 
symptomatic PAD than in healthy patients. The risk of heart attack, stroke or cardiovascular death is even higher, 
reaching almost 4% within one year, nearly equal to the risk for patients with coronary artery disease (CAD). In 
those patients, the 5-year mortality risk is estimated at 10–15%, with cardiovascular disorders being the most 
likely cause of death. In patients with critical limb ischemia, the risk of cardiovascular death within one year can be 
as high as 25% and the risk of amputation — 30%.
It is estimated that the global population of patients with PAD is over 120 million. The incidence of the diseases 
is 3–10%, but in patients aged 70 and more, the incidence increases to 14–29%. In Poland, around 4,000 people 
are hospitalized every year for PAD of lower limbs. The number of PAD-related amputations is over 9,000 per year. 
Although the methods of PAD diagnosis (e.g. ABI) are often easy and non-invasive, they are scarcely used in clinical 
practice. Also, optimal conservative management in the form of quitting smoking, modifying the cardiovascular risk 
factors and supervised exercise is often overlooked. 
PAD is a major issue not only for vascular surgery, but also for many other medical specializations, including 
angiology, general medicine, cardiology, or diabetology. As a result of long waiting times for the next visit and lack 
of access to patient programmes and reimbursed drugs, patients with PAD often report to the doctor when their 
condition is very serious. Despite the 2017 ESC guidelines on the diagnosis and treatment of peripheral artery 
disease, prepared together with ESVS, not all healthcare professionals have access to the latest knowledge on PAD 
diagnosis and treatment. Unfortunately, though published recently, the ESC’s guidelines do not include some of 
the recent studies, among them the possibly breakthrough COMPASS trial which has the potential to change the 
paradigm of management of patients with PAD.
We must bear in mind that the population with PAD is a difficult patient group who need new treatment methods 
and optimization of the existing ones in order to visibly improve diagnosis, treatment and prognosis.
              Prof. Arkadiusz Jawień, MD PhD                           Prof. Tomasz Zubilewicz, MD PhD 
President of the Polish Society for Vascular Surgery           Editor-in-Chief „Acta Angiologica”
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Abbreviations:
ABI — ankle–brachial index 
ACC — American College of Cardiology
ACE — angiotensin converting enzyme
ACEI — angiotensin-converting-enzyme inhibitors 
ADP — adenosine diphosphate
AH — arterial hypertension 
AHA — American Heart Association 
Angio-MR — magnetic resonance angiography
ARB — angiotensin receptor blockers
ASA — acetylsalicylic acid
CAD — coronary artery disease 
CLTI — chronic limb-threatening ischemia
CV — cardiovascular system 
DAPT — dual antiplatelet therapy
EBM — evidence-based medicine
ESC — European Society of Cardiology
ESVS — European Society for Vascular Surgery
FDA — Federal Drug Administration
GLP-1 — glucagon-like peptide-1
GPS — good practice statement 
HDL-C — high-density lipoprotein cholesterol
HIV — human immunodeficiency virus
INR — international normalized ratio 
LDL-C — low-density lipoprotein cholesterol
LEAD — lower extremity artery disease
MACE — major adverse cardiac events
MWD — maximum walking distance 
NNT — number needed to treat
NOAC — novel oral anticoagulants other than vitamin 
K antagonists
OAC — oral anticoagulants
PAD — peripheral artery disease 
PAR-1 — proteinase-activated receptor 1
PCSK9 — proprotein convertase subtilisin/kexin  
type 9 
PFWD — pain-free walking distance
PTD — Polish Diabetological Association 
SAPT — single antiplatelet therapy
SGLT-2 — sodium/glucose cotransporter 2
TBI — toe–branchial index 
TcPO2 — transcutaneous oxygen pressure 
TIA — transient ischemic attack of the central nervous 
system
VKA — vitamin K antagonist
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1. Introduction
The first decade of the 21st century has seen major 
progress in the diagnosis and treatment of peripheral 
artery disease (PAD). The introduction of new state-
of-the-art techniques of intravascular treatment, new 
anticoagulants and new generations of statins resulted 
in a large number of new scientific reports and pub-
lications allowing a more objective assessment of the 
outcomes of various treatment and management meth-
ods. Given the new data available and the high risk of 
circulatory diseases in the Polish population, it appears 
necessary to develop Polish guidelines on the conserva-
tive management of the lower extremity artery disease 
(LEAD), focusing in particular on the pharmacotherapy 
of patients with intermittent claudication. The guide-
lines should take into account the results of the latest 
studies and trials, and the international guidelines on the 
management of LEAD. The purpose of this publication 
is to organize the available knowledge in an accessible 
manner so that it could be more efficiently used by all 
actors involved in PAD management. The Workgroup 
decided to restrict the scope of this study to the lesions 
in lower extremities secondary to atherosclerosis and 
the conservative management thereof, not including the 
issue of PAD in other areas of the vascular system, and 
to the indications for revascularization treatment and 
the methods of revascularization in patients with LEAD. 
The authors had to choose the system of classifica-
tion of the strength of the guidelines and the supporting 
scientific evidence, especially given that the literature of 
the subject, including the international guidelines on the 
management of patients with LEAD, had been using dif-
ferent approaches. Following the analysis of publications 
on the subject at hand from the preceding 10 years, 
the system applied in the guidelines of the European 
Society of Cardiology (ESC) was adopted. The system 
is based on 4 classes of recommendations indicating the 
strength of the recommendation (I, IIa, IIb, III), and 3 
levels of evidence on which the recommendations are 
based (A, B, C). Both information should be provided 
together with a specific recommendation.
It should be pointed out that the position set out 
below, as well as the strength of individual recom-
mendations, are not legally binding and thus the au-
thors thereof cannot be legally liable for them. The 
following guidelines reflect the current state of the art 
in accordance with the principles of Evidence-Based 
Medicine (EBM) and are aimed at facilitating the 
standardization of medical care of patients with LEAD 
in Poland, in particular, the patients suffering from 
intermittent claudication. Much consideration was 
given to the complex issues related to anticoagulation 
therapy of patients with LEAD who often suffer from 
comorbidities which affect the indications for the use 
of anticoagulants (e.g. coronary artery disease or atrial 
fibrillation).
1.1. Purpose
The purpose of this publication on the conservative 
management of LEAD secondary to atherosclerosis is 
to organize the available knowledge and allow proper 
management of LEAD in line with the principles of 
EBM. The Workgroup’s task of developing the guide-
lines involves not only reconciling the knowledge 
from the latest scientific studies, but also preparing 
educational tools and guideline implementation pro-
grammes, including abridged versions, summarizing 
slides, bulletins listing the main premises, summary 
cards for non-specialists, and digital versions for use 
in electronic appliances (such as smartphones). Digital 
versions of the source document will be abridged; 
therefore, the full text of the guidelines should be 
referenced.
1.2. Patient groups to whom the position 
applies
The developed position applies to patients with LEAD 
secondary to atherosclerosis.
1.3. Receivers of the position
The receivers of the position are doctors of all special-
izations who provide both general and specialized care 
for the aforementioned patients with LEAD.
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1.4. Intervention types provided  
for in the position
The recommendations provided in the position include 
the diagnostic tests used for the diagnosis and athero-
sclerotic assessment of LEAD, as well as pharmacother-
apy and non-pharmacological methods of management 
thereof (excluding interventional treatment). 
1.5. Instructions on the use of the position
The position set out herein should not be viewed as 
a legally binding standard of care for all patients, since 
the document contains only guidelines for management, 
and the recommendations should aid doctors in making 
optimal decisions in everyday clinical practice. The 
proper patient care always depends on the individual 
conditions of the patient, the available and feasible 
methods of treatment, and many more factors; deci-
sions on the applied management must always be made 
by the attending physician or the medical team, in con-
sultation with the patient or, if necessary, the patient’s 
guardian. The authors of the guidelines encourage 
doctors and medical professionals to implement and 
popularize the following guidelines for the management 
of adult patients with LEAD.
2. Methodology
2.1. Workgroup
The position was developed by the Polish experts/ 
/specialists in angiology, hypertension management, 
vascular surgery, internal medicine and cardiology. 
The Workgroup was composed of Professor Zbigniew 
Krasiński, DMSc, PhD (Head of Workgroup), Professor 
Zbigniew Gaciong, DMSc, PhD, Professor Tomasz Ur-
banek, DMSc, PhD, Filip Szymanski, DMSc, PhD, and 
Radosław Kowalewski, DMSc, PhD
2.2. Description of the process of developing 
the position and associated documents
Formulating the propositions of guidelines, the experts 
took into account the 2017 ESC guidelines on the diag-
nosis and treatment of PAD, developed together with 
the European Society for Vascular Surgery [1], the 2016 
guidelines of the American Heart Association (AHA) 
and the American College of Cardiology (ACC) on 
the management of patients with LEAD [2], the 2015 
guidelines of the Society for Vascular Surgery on the 
management of asymptomatic LEAD and intermittent 
claudication [3], and other scientific studies and pub-
lications from recent years, especially those released 
after the publication of the aforementioned guidelines.
Formulating the recommendations in the Polish 
position, the experts analyzed the source guidelines 
in terms of applying them in a Polish setting. The de-
veloped propositions for the recommendations were 
discussed in detail during meetings. Any disputes were 
discussed and settled. The preliminary version of the 
Polish position was then submitted for external con-
sultations and reviews. Any justified comments on the 
substance of the guidelines were taken into consider-
ation by the Workgroup. All experts in the Workgroup 
accepted the final version of the document.
2.3. Classification of the strength  
of recommendations and level of evidence
In this document, the system of classification of recom-
mendations and levels of evidence proposed by the ESC 
was adopted (Tables 1A and 1B). The level of evidence 
was assessed as high (A), moderate (B) or low (C). The 
strength of a recommendation was classified based 
on the authors’ opinion that the given management 
procedure was justified and would bring more benefits 
than harm. Class I (“it is recommended”) and III (“it 
is not recommended”) are strong recommendations, 
while class IIa (“it is reasonable”) and IIb (“may be 
reasonable”) are conditional/weak recommendations. 
In the absence of existing recommendations, related 
e.g. to the results of the latest studies, the Workgroup 
attempted to formulate the so-called good practice 
statement (GPS), i.e. a reconciled opinion of all experts. 
3. Epidemiological data,  
clinical assessment, diagnosis
3.1. Prevalence and causes  
of chronic limb ischemia
The lower extremity artery disease (LEAD) is one 
of the most frequent peripheral artery diseases, the 
prevalence of which increases with the age of the ob-
served population. On the basis of epidemiological data, 
the incidence of chronic limb ischemia is estimated at 
3–10%, and in the population aged 70 or above, occurs 
15–20%, more frequently in males [4]. In its initial stage, 
the disease is asymptomatic. In the studies based on the 
ankle-brachial index (ABI), which allows an objective 
diagnosis, the ratio of asymptomatic patients to the 
general number of confirmed cases ranges from 1:3 
to 1:5 [1, 4–6]. The incidence of critical limb ischemia 
is 200–1,000 new cases per 1 million members of the 
population and is significantly higher in diabetic popula-
tions [1, 4, 5]. The key factors leading to LEAD include 
age, smoking, hyperlipidemia, the co-occurrence of 
diabetes or impaired glucose tolerance, and arterial 
hypertension [1, 4, 5]. Other factors which play a part 
in the development of chronic ischemia include sex, 
ethnicity, vascular lesions in kidney failure, as well as 
the C-reactive protein level, hyperfibrinogenemia and 
hyperhomocysteinemia [1]. Genetic factors are also 
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Table 1A. Classes of recommendations
I Evidence from scientific studies and/or general agreement that a given procedure or treatment is beneficial,  
useful and effective
Is recommended…
IIa Weight of evidence and/or opinion is in favour of usefulness or efficacy of the given procedure or treatment
Should be considered…
IIb Usefulness or efficacy of the given procedure or treatment is less well established by evidence and/or opinion
May be considered…
III Evidence from scientific studies and/or general agreement that the given procedure or treatment is not useful  
or effective, and in some cases may be harmful
Is not recommended…
Table 1B. Level (quality) of evidence
A — Data derived from multiple randomized clinical trials or meta-analyses
B — Data derived from a single randomized clinical trial or large non-randomized studies
C — Consensus of opinion of the experts and/or data derived from small studies, retrospective studies, registries
considered, although their identity and impact are still 
being studied [1, 5].
The lesions causing chronic limb ischemia are often 
accompanied by atherosclerotic lesions in other areas of 
the vascular system, which increase the cardiovascular 
risk, in particular, the risk of a heart attack and ischemic 
stroke [5]. In patients with atherosclerotic LEAD, the 
risk of mortality caused by coronary artery disease is 
increased 4-fold, and the incidence of brain ischemic 
episodes increases 2- to 3-fold [7–10]. In most cases, 
chronic lower limb ischemia is accompanied by ather-
osclerotic arterial lesions (95-98% of cases), although 
the chronic lower limb ischemia may also be caused by 
other diseases or clinical conditions [1, 4]. These include 
inflammatory vascular diseases, history of arterial em-
bolism, vascular stenosis or occlusion in compressive 
lesions or sustained injuries and the consequences 
thereof, thrombosed popliteal artery embolism, com-
plications of intra-arterial injections, or the less frequent 
vascular tumours [1, 4]. Diabetes is a key factor in the 
development of atherosclerotic lesions. Diabetic le-
sions usually coincide with the atherosclerotic process 
and lead to increased vascular wall rigidity not only by 
thickening but also by intravascular calcifications [4, 5]. 
In terms of symptomatology and treatment options, the 
involvement of lower leg arteries, a typical condition 
in diabetic patients, is of particular clinical importance, 
as it is a risk factor of critical ischemia in patients from 
this group [1, 4]. 
3.2. Symptomatology and classification  
of chronic limb ischemia
Most patients do not experience clinical symptoms and 
the condition can be identified on the basis of decreased 
ABI level (< 0.90) or the lack of pulse in leg arteries. 
The latest edition of ESC guidelines distinguishes 
a patient subgroup with “masked”, i.e. a hidden form 
of LEAD. Those patients can suffer from severe disease 
but not report any symptoms due to the inability to 
cover a distance long enough for LEAD symptoms to 
manifest themselves (e.g. because of disability caused 
by another condition, such as heart failure), and/or 
reduced pain sensitivity (e.g. in patients with diabetic 
neuropathy) [1]. The patients in this group are usually 
elderly individuals, often suffering from neuropathy and 
other comorbidities. The subgroup with masked LEAD 
is exposed to high risk of limb-related incidents, which 
explains why some patients rapidly deteriorate from 
asymptomatic to sever LEAD. 
One of the most typical symptoms of LEAD is inter-
mittent claudication, which may affect different parts of 
the limb depending on the level of vascular occlusion/
stenosis. The most frequent location of single-level ste-
nosis in lower extremities is the femoral artery; howev-
er, as the disease progresses, multilevel atherosclerotic 
lesions develop. Clinically, the presence of occlusion 
and/or stenosis in the aorto-iliac or femoral-popliteal 
segment, and peripheral lesions involving the lower leg 
and foot can be distinguished [5]. The lesions are often 
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Table 2A. Fontaine classification of chronic limb ischemia
Stage Clinical symptoms
I Asymptomatic
IIa Mild claudication — claudication distance 
above 200 m
II b Moderate or severe claudication — claudica-
tion distance below 200 m
III Ischemic rest pain
IV Ulceration or gangrene
Table 2B. Rutherford classification of chronic limb ischemia
Category Clinical symptoms
0 Asymptomatic
1 Mild claudication
2 Moderate claudication
3 Severe claudication
4 Ischemic rest pain
5 Minor tissue loss
6 Major tissue loss
multilevel or located also in other areas of the vascular 
system. The occlusion of the femoral artery causes in-
termittent claudication which usually affects the lower 
leg muscles. The occlusion in the aorto-iliac segment 
can cause gluteal claudication — this condition usually 
accompanies the occlusion of the internal iliac artery. 
Stenosis or occlusion of iliac and/or pelvic vessels can 
also cause erectile dysfunction in men. In the case of 
occlusion of the lower leg vessels and impaired blood 
flow to the foot, the most typical symptoms, aside from 
lower leg pain, are observed in the foot [5, 11]. 
The severity of LEAD symptoms depends on factors 
related to both the location and extent of atherosclerot-
ic lesions and the degree of development of collateral 
circulation [1, 4]. Aside from intermittent claudication, 
in the case of a chronic form of the disease, a number of 
irregularities can be observed in physical examination, 
such as muscular dystrophy, poor filling of superficial 
veins, loss of hair, weak capillary action, and paleness 
of the limb skin. If the ischemic symptoms deteriorate, 
necrotic lesions or ulceration can occur. Necrotic le-
sions (dry or liquefactive) initially affect the most distal 
parts of the extremity (toes, forefoot, calcaneal tuber 
area), and sites exposed to local chronic injuries (caused 
e.g. by compression), such as toes, heel and the 1st and 
5th metatarsal bone heads. The progression of athero-
sclerotic lesions and deteriorating ischemia can lead to 
critical limb ischemia, which deteriorates prognosis. In 
patients with stable intermittent claudication, the risk of 
amputation over a 5-year follow-up period is relatively 
low; with proper management, it is approx. 2–3% 
within 5 years, and in 5–10% of those cases, critical 
limb ischemia will occur [4]. The risk of deterioration 
of the symptoms of intermittent claudication in the 
further 5 years of the disease is estimated at 10–20%, 
whereby the risk is highest in the first year following 
the diagnosis (6–9%) and reduced in subsequent years 
(2–3%/year) [12]. Differential diagnosis of intermittent 
claudication should take into consideration other poten-
tial causes of claudication, including claudication related 
to neurological diseases (e.g. nerve root or spinal cord 
compression), claudication of venous origin (occlusion, 
e.g. in the proximal segment of the venous system), 
chronic compartment syndrome, and other clinical 
conditions causing pain of the lower extremities [4]. 
A prerequisite for the diagnosis of critical limb ischemia 
is the confirmation of pain persisting for 2 weeks, or 
necrotic signs (stage III or IV ischemia according to Fon-
taine classification). Persistent pain in ischemia usually 
occurs with the blood pressure at the ankle below 50 
mm Hg, or the pressure in big toe below 30 mm Hg. 
The level of partial oxygen pressure in percutaneous 
measurement (tcPO2) considered to be critical is below 
30 mm Hg [4]. The proposed and applied leg ischemia 
classifications according to Fontaine and Rutherford are 
outlined in Tables 2A and 2B. 
3.3. Diagnosis of chronic limb ischemia  
— clinical assessment and additional tests
The basic method for diagnosing chronic limb ischemia 
is a physical examination. Due to the possible lack of 
pulse in the limbs of some patients unrelated to LEAD, 
as well as the subjective nature of the ailments, the diag-
nostic algorithm must include additional tests [1, 4, 5]. 
Aside from assessing the pain and intermittent clau-
dication, an important element of the physical examina-
tion is collecting the history of other atherosclerotic cir-
culatory diseases, such as the coronary artery disease, 
stroke, transient ischemic attack, chronic mesenteric 
ischemia and other conditions of the circulatory system, 
such as arterial hypertension, arrhythmias (including 
atrial fibrillation) and heart failure. Equally important 
is the assessment of comorbidities, obesity and the 
patient’s habits (physical activity, smoking, a diet with 
high fat or carbohydrate content) [1]. It is necessary to 
assess the cardiovascular risk factors identified mainly 
on the basis of laboratory tests, such as lipid disorders, 
diabetes or kidney failure, which affect the progression 
of ischemic lesions [1]. Aside from the assessment of 
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the site condition, the physical examination must also 
include measuring the pulse in typical sites on lower 
extremities (femoral artery, popliteal artery, dorsal 
artery of the foot, and posterior tibial artery).
In order to acquire an objective assessment of the 
stage of ischemia, the clinical assessment should be 
supplemented with additional tests. One of the most 
basic test methods is the measurement of ABI [1, 4]. 
Decreased ABI level correlates with the increase of 
cardiovascular risk [1, 4, 13–16]. It is generally accepted 
that ABI level ≤ 0.9 signals chronic limb ischemia (limit 
values 0.9–1.0; normal range: 1–1.4). In the event of 
measuring different pulse values in the dorsal artery of 
the foot and the posterior tibial artery of the same limb, 
the higher of the two values is used in the diagnosis of 
LEAD [4]. In patients with diseases causing increased 
arterial wall rigidity, e.g. diabetes, ABI level may increase 
to above 1.4; in such cases, the parameter cannot be 
used in the assessment of the severity of ischemia [1, 4, 
5]. In patients with diabetes and the potential increase 
of lower leg arterial wall rigidity, the parameter allowing 
a more reliable assessment of the blood flow in the limb 
is the toe-brachial index (TBI). The measurement is 
taken by placing the sleeve on the big toe; the pressure 
value is read by the continuous-wave Doppler ultra-
sound transducer or a plethysmograph. TBI values be-
low 0.7 are considered abnormal [17]. In patients with 
intermittent claudication, in order to objectively assess 
the distance covered without pain, a treadmill walking 
test can be performed. It is recommended to perform 
the standardized test, with the treadmill inclination of 
12 degrees and speed of 3.2 km/h [1, 4, 5]. The tcPO2 
measurement may be useful both in the identification of 
chronic limb ischemia and the assessment of healing of 
wounds of ischemic origin. Other methods of assessing 
the microcirculation vessels, including laser Doppler 
flowmetry and capillaroscopy, are used much less fre-
quently and mainly for scientific purposes. 
The next group of additional tests performed in 
patients with LEAD are imaging test. In most cases, 
a duplex Doppler ultrasound examination is indicated, 
as it allows locating and assessing the stage of stenosis/ 
/occlusion. If the patient requires surgical treatment, 
a more objective and more comprehensive assessment 
of limb arteries is needed, including the aorta and iliac 
arteries. The first-line test is computed tomography 
(CT) angiography; however, as the method employs 
a contrast agent, it may deteriorate renal function, 
especially in patients who are already suffering from 
renal impairment. An alternative method is magnetic 
resonance angiography (MRA), but the availability of this 
test is still limited, the image recording time is much 
longer, and there is also the risk of contrast agent-in-
duced complications [1, 4]. MRA can be performed 
without the contrast agent but at the cost of worse 
visibility of the lesions and a higher number of artefacts. 
Diagnosis of small vessels is challenging, especially an 
objective assessment of the vessels of the lower leg 
and the foot, particularly when vessel wall calcifications 
are present, e.g. in diabetic patients. The reference 
method providing the most accurate and precise image 
of the lower leg and the foot (in particular in patients 
with diabetic peripheral lesions) is still conventional 
angiography [1, 4]. 
Angiography using puncture technique is currently 
considered justified mainly when a simultaneous ther-
apeutic procedure (revascularization) is planned. An 
exception is the aforementioned diagnosis of the vessels 
of the lower leg and the foot in diabetic patients with 
peripheral lesions since invasive angiography is able to 
image this vascular segment much more efficiently than 
other methods.
The recommendations for the medical interview, 
the physical examination and diagnostic tests in patients 
with atherosclerotic LEAD are outlined in Table 3.
4. General principles of management, 
treatment with exercise
The management of patients with LEAD involves 
two main elements: treatment in order to reduce the 
global cardiovascular risk, and treatment aimed at the 
symptoms and risk related to the occurrence of lesions 
in the arteries of lower extremities, in order to reduce 
the symptoms in the extremity and/or save the extrem-
ity from amputation. The management recommended 
for reducing the global cardiovascular risk, involving 
non-pharmacological methods and pharmacotherapy, 
is similar for all patients with PAD, regardless of the 
area of the vascular system in which the symptoms of 
atherosclerotic lesions occur. The treatment targeting 
local lesions in the arteries of lower extremities is typical 
for LEAD management.
Non-pharmacological methods — according 
to the 2017 ESC guidelines [1] on the management of 
patients with PAD, the following is recommended for 
all patients in this group: 
1) quitting smoking (class of recommendation Ib);
2) healthy diet and physical exercise (class of recom-
mendation Ic).
The notion-pharmacological prevention strate-
gies can also be beneficial in terms of reducing limb 
incidents. In terms of both the improvement of the 
symptoms and the reduction of the cardiovascular 
risk, the most beneficial strategy is the combination 
of the recommended methods, i.e. quitting smoking 
alone will have little effect on the walking distance, 
but combined with exercise training, it will improve 
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Table 3. Medical interview, physical examination and diagnostic tests for patients with atherosclerotic lower extremity artery 
disease
Recommendations and instructions Class of  
recommendation
Level (quality)  
of evidence
Medical interview and physical examination
In the case of patients with increased risk of LEAD (see Table 4), medical interviews 
should be collected on the symptoms in lower extremities, among them intermittent 
claudication and unusual exercise symptoms, deterioration of walking efficiency, ischemic 
rest pain and non-healing wounds of lower extremities. Also, the presence of other  
circulatory diseases secondary to atherosclerosis and their risk factors should be assessed
I C
In patients from the increased LEAD risk group (see Table 4) and/or with the symptoms 
suggesting LEAD, the vascular system of the lower extremities should be examined, in-
cluding the assessment of pulse in the arteries of the lower extremities, murmurs above 
the femoral arteries, and visual examination of the lower extremities
I C
Diagnostic tests
ABI measurement is recommended for patients with clinically suspected LEAD on the 
basis of the medical interview or the physical examination
I C
ABI measurement may be considered for patients in the increased LEAD risk group  
(see Table 4) without the clinical suspicion of LEAD on the basis of the medical  
interviews or the physical examination
IIb C
ABI measurement is recommended as the first-line method for diagnosing LEAD I C
In the event of clinical suspicion of LEAD in patients with ABI > 1.4, or in the event  
of confirmed diabetes, the measurement of the toe-brachial index is recommended
I C
In the patients with symptomatic LEAD who are considered for revascularization,  
anatomical imaging methods are recommended, such as duplex ultrasound (first-line 
method), computed tomography angiography or magnetic resonance angiography
I C
ABI: ankle-brachial index; LEAD: lower extremity artery disease
Table 4. Patients with increased risk of atherosclerotic lower extremity artery disease (based on [1, 2])
Other atherosclerotic circulatory disease (coronary artery disease, peripheral artery disease in another area of the  
vascular system)
Heart failure
Abdominal aortic aneurysm
Chronic kidney disease
Age ≥ 65
Patients are aged < 65 with atherosclerosis risk factors (smoking, hyperlipidemia, arterial hypertension, diabetes), especially 
those in high and very high cardiovascular risk according to ESC guidelines on the prevention of circulatory diseases [18]
Patients aged > 50 with a family history of LEAD
ESC: European Society of Cardiology; LEAD: lower extremity artery disease
the walking distance considerably. On the other hand, 
smoking deteriorates LEAD in patients with intermit-
tent claudication and increases the risk of amputation 
[18, 19].
Pharmacotherapy — each patient with PAD 
should receive pharmacotherapy as recommended 
in the guidelines in order to reduce the incidence 
of cardiovascular events and events related to ex-
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tremities. The pharmacotherapy recommended for 
patients with PAD includes first of all anticoagulation 
drugs (mainly antiplatelet agents) and statins, and 
treatment related to any additional risk factors, such 
as co-occurring diabetes or arterial hypertension 
(see chapter 5). 
The ESC guidelines emphasize that even if patients 
with LEAD are asymptomatic, the cardiovascular risk 
remains high and most strategies of cardiovascular 
events prevention are beneficial to them, in particular, 
strict control of the risk factors. An exception is an 
antiplatelet treatment which is recommended mainly 
for patients with symptomatic LEAD; no benefits to 
asymptomatic patients of administering antiplatelet 
agents have been confirmed.
The recommendations on the reduction of cardio-
vascular risk in patients with atherosclerotic LEAD are 
outlined in Table 5. 
Symptomatic treatment — in patients with 
intermittent claudication, the treatment aimed at im-
proving LEAD symptoms is based mainly on exercise 
training (see below). If the patient’s daily activities 
are significantly disturbed, revascularization should 
be considered, combined with exercise therapy; 
this also applies to the situations when activity is 
significantly reduced despite the exercise therapy 
and other treatment methods. The details of the 
revascularization treatment of the arteries of lower 
extremities exceed the scope of this study. The drugs 
improving LEAD symptoms (mainly intermittent clau-
Table 5. Recommendations on reducing the cardiovascular risk in patients with atherosclerotic lower extremity artery disease
Recommendation Class of  
recommendation
Level (quality)  
of evidence
Non-pharmacological methods
Quitting smoking is recommended for all patients with LEAD I B
A healthy diet and physical exercise are recommended for all patients with LEAD I C
Lipid disorders treatment
Treatment with statins is recommended for all patients with LEAD I A
For patients with LEAD, it is recommended to reduce the LDL-C level to < 1.8 mmol/L  
(70 mg/dL), or ≥ 50%, if the initial LDL-C level is 1.8-3.5 mmol/L (70–135 mg/dL)
I C
Anticoagulation treatment
Long-term anticoagulation treatment is recommended for all patients with symptomatic 
LEAD or after revascularization due to LEAD (see Table 8)
I Aa
Arterial hypertension treatment
Non-pharmacological methods should be applied according to the general standards I A
For patients with LEAD and arterial hypertension, the recommended target blood  
pressure is < 140/90 mm Hgb
I A
All main classes of hypotensive drugs can be used, depending on the co-occurring  
clinical conditions
IIa C
The inhibitors of the renin-angiotensin system (ACEI or ARB) should be considered  
as the first-line drugs for patients with LEAD and arterial hypertension
IIa B
Beta-adrenolytics should be considered for patients with LEAD and indications for  
beta-adrenolytic therapy due to comorbidities (e.g. history of heart attack, heart failure 
with impaired left ventricular contractile function)
IIa B
ACEI should not be combined with ARB in treating arterial hypertension III A
Diabetes treatment
Strict glycemic control and standard treatment of diabetes are recommended  
for diabetic patients with LEAD
I C
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; LDL-C: cholesterol in low-density lipoprotein fraction; LEAD: lower extremity 
artery disease
a Patients with symptomatic LEAD — the level of evidence A; patients after revascularization — the level of evidence C 
b With the exception of patients, for whom higher target values might be indicated, e.g. elderly patients with frailty syndrome
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Table 6. Recommendations on symptomatic treatment of patients with intermittent claudication
Recommendation Class of  
recommendation
Level (quality) 
of evidence
Statins
Regardless of the benefits in terms of reducing cardiovascular risk, statins are also  
recommended to improve the walking distance
I B
Exercise therapy
Supervised walking training is recommended for all patients with chronic lower limb  
ischemia who are able to exercise. The patient should attend walking training sessions 
for at least 3 months, and the exercise on the treadmill should be intense enough  
to induce intermittent claudication; after each episode of claudication, the patient  
should rest
I A
If supervised exercise training is not possible or available, unsupervised exercise  
training/physical exercise is recommended
I C
Treatment extending the walking distance
For patients with intermittent claudication, for whom elimination of risk factors and 
walking training is not bringing sufficient improvement, symptomatic pharmacotherapy 
may be considered to extend the patient’s walking distance (See Table 11)
IIb A
Revascularization
If despite the exercise therapy and other methods, the patient’s normal functioning  
remains disturbed, revascularization should be considered
IIa C
If the patient’s normal functioning remains severely disturbed, revascularization  
combined with exercise therapy and other methods should be considered
IIa B
dication) play a supporting role and are discussed in 
detail in item 5.3.
The recommendations on the symptomatic treat-
ment of patients with intermittent claudication are 
outlined in Table 6.
4.1. Exercise therapy
Aside from reducing cardiovascular risk, systematic 
physical exercise, in particular, walking, is essential 
in the treatment of the symptomatic LEAD. Walking 
training, preferably supervised, not only extends the 
walking distance by improving the efficiency of the local 
collateral circulation but is also beneficial to the circu-
latory system by improving the endothelial function, 
reducing inflammation, increasing the pain threshold, 
stimulating angiogenesis, improving cell metabolism and 
reducing blood viscosity. Exercise therapy improves the 
performance of the circulatory system and the overall 
quality of life [1, 20–23]. 
The ESC guidelines [1] recommend exercise therapy 
for patients with intermittent claudication, preferably 
in the form of properly supervised walking training 
(class of recommendation Ia), and if supervised training 
is unavailable, unsupervised training is recommended 
(class of recommendation Ic). In the case of supervised 
exercise therapy, exercise 3 times a week is usually 
recommended, starting with a 30-minute training and 
gradually extending its length to 60 minutes. As soon 
as the moderate (sub-maximal) pain severity is reached 
during training on the treadmill, the patient should rest 
until the pain disappears. The next exercise cycle should 
follow the same principles, and the total length of the 
training session should be gradually extended. As the 
claudication distance is gradually extended with exer-
cise, the treadmill pace and incline may be increased 
(the recommended initial settings are based on the 
assumption that pain will appear after 3-5 minutes of 
walking) [4]. According to a review of data from the 
Cochrane database on 30 randomized trials, the walk-
ing training extended the maximum walking distance 
(MWD) and pain-free walking distance (PFWD) [24]. 
Exercise therapy also improved the overall quality of 
life. The ESC guidelines state that supervised exercise 
therapy is safe and that routine screening for heart dis-
eases is not required prior to the therapy [25], however, 
the patient should undergo a clinical assessment of the 
cardiopulmonary reserve and comorbidities in terms 
of his/her tolerance of the planned exercise therapy. 
The minimum duration of exercise therapy is 3 months 
[24, 26]. The walking training also improves the long-term 
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treatment outcomes in patients undergoing revascu-
larization [27].
Supervised exercise therapy is more efficient than 
unsupervised one [1, 26, 28, 29], but if appropriate 
supervision cannot be provided to the patient, then 
exercise therapy at home is a useful alternative, usually 
in the form of intensified walking, as this type of training 
also improves the overall quality of life and the walking 
performance [28, 30]. If the patient is unable to walk, 
alternative types of exercise can be used (e.g. bicycle 
riding, strength training or rowing machine for upper 
limbs — e.g. for patients after amputations), since those 
exercised have also been proven to be effective [29]. 
5. Pharmacotherapy
The objectives of pharmacotherapy in patients with 
LEAD include:
1. Reducing the risk of cardiovascular mortality and 
morbidity.
2. Reducing the risk of lower limb-related incidents.
3. Reducing the LEAD symptoms (mainly intermittent 
claudication).
4. Improving the treatment outcomes after revascu-
larization (percutaneous or surgical).
In this patient group, pharmacotherapy involves 
two main elements: treatment to reduce cardiovas-
cular risk and symptomatic treatment. Next, to the 
non-pharmacological methods, pharmacotherapy is 
the basic method of reducing the global cardiovascular 
risk in patients with LEAD, with a major impact on 
the overall prognosis. In order to reduce the risk of 
cardiovascular mortality and morbidity, mainly stating 
(see item 5.1.1) and antiplatelet drugs (see item 5.2) 
are used, and treatment for other risk factors, such as 
co-occurring diabetes (see 5.1.2) or arterial hyperten-
sion (see 5.1.3). Anticoagulation drugs are used mainly 
in patients with conventional indications for chronic 
oral anticoagulation, such as atrial fibrillation or venous 
thromboembolism. The data from the recently com-
pleted clinical trials indicate a potential role of direct 
oral anticoagulants (DOACs) in the management of 
LEAD (see 5.2). Some of the aforementioned drugs, in 
particular, the anticoagulants and statins, also reduce 
the risk of lower limb-related incidents and improve the 
outcomes of percutaneous or surgical revascularization.
Pharmacotherapy improving the LEAD symptoms 
(intermittent claudication) and/or improving the lower 
extremity function (see 5.3) is only supplementary 
to other methods of symptomatic treatment, such 
as walking training therapy and revascularization. 
Among the many tested pharmacological agents, the 
most significant improvement of the walking distance 
in patients with LEAD were achieved with cilostazol 
and naftidrofuryl; the usefulness of other drugs is less 
well-confirmed or unconfirmed, and they are usually 
not recommended by international guidelines. Some 
drugs used mainly to reduce the global cardiovascular 
risk can also play a role in symptomatic treatment, in 
particular, statins. 
5.1. Cardiovascular risk factors control
5.1.1. Hypolipidemic therapy in patients  
with lower extremity artery disease
Hypolipidemic therapy, mainly with the use of statins, 
which are pleiotropic drugs, reduces cardiovascular 
morbidity and mortality, and the overall mortality in pa-
tients with overt circulatory diseases, including patients 
with PAD. According to ESC guidelines, it is recom-
mended for all patients with PAD to reduce the serum 
level of low-density lipoprotein cholesterol (LDL-C) 
to < 1.8 mmol/L (< 70 mg/dL), or by ≥ 50%, if the 
initial LDL-C level is 1.8–3.5 mmol/L (70–135 mg/dL) 
[1]. This corresponds to the objectives of treatment in 
patients from the very high cardiovascular risk group [3]. 
The recent recommendations of the Cardiovascular 
Pharmacotherapy Section (CPS) of the Polish Cardiac 
Society, published in the so-called 3rd Declaration of 
Sopot, specify that all patients with PAD (general 
atherosclerosis) and additional risk factors should be 
qualified into the highest risk group, called the extreme 
risk group in the CPS nomenclature, so their target 
serum LDL levels should be LDL < 35 mg/dL (< 0.9 
mmol/L) (Table 7).
According to the current guidelines of the Europe-
an Society of Cardiology and other scientific bodies, 
each patient with LEAD must receive statins from the 
attending physician (class IA recommendation) [1–3]. 
The results of the studies conducted thus far have 
shown that using statins reduces overall mortality and 
the incidence of cardiovascular events in patients with 
various stages of LEAD [31, 35]. Statins also significantly 
improve the walking distance until pain occurs and the 
maximum walking distance, and may reduce the inci-
dence of adverse events in the limbs of patients with 
LEAD [34] (see 5.3).
In those patients who do not achieve the therapeutic 
goals with statins alone, statin therapy combined with 
ezetimibe can be beneficial [36]. A randomized clinical 
trial did not show a reduction of the cardiovascular risk 
in LEAD patients treated with bezafibrate as compared 
to placebo [37]. 
Recently, results of trials were published showing 
that the new, strong hypolipidemic drugs, proprotein 
convertase subtilisin/kexin type 9 (PCSK9), further con-
siderably reduced the LDL-C levels and improved the 
clinical outcomes in patients with PAD. In the FOURIER 
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Table 7. Target low-density lipoprotein levels in relation to the cardiovascular risk profile (authors’original contribution).
Risk category Presence of disease, risk factors or 10-year Pol-SCORE risk Target LDL-C level
Extremely 
high
Stenting for left main coronary artery disease and/or multivessel coronary artery  
disease (complex percutaneous coronary intervention due to multivessel coronary 
artery disease)
Generalized atherosclerosis — involving multiple vascular beds with  
additional risk factors
Progression of atherosclerotic cardiovascular disease despite achieving  
and maintaining LDL-C level < 55 mg/dL (< 1.4 mmol/L)
< 35 mg/d.
(< 0.9 mmol/l)
Very high Progression of atherosclerotic cardiovascular disease despite achieving  
and maintaining LDL-C level< 70 mg/dL (< 1.8 mmol/L)
Acute coronary syndrome, established coronary, carotid, or peripheral arterial 
disease
Previous revascularization
Pol-SCORE risk > 20%
Diabetes or stage 3–4 chronic kidney disease with one or more risk factors
Familial hypercholesterolemia
History of premature atherosclerotic cardiovascular disease (< 55 years in men,  
< 65 years in women)
Established cardiovascular disease in patients with diabetes or stage 3–4 chronic 
kidney disease
< 55 mg/dl
(< 1.4 mmol/l)
High ≥ 2 risk factors and Pol-SCORE risk 10–20%
Diabetes or stage 3–4 chronic kidney disease without other risk factors
< 70 mg/dl
(< 1.8 mmol/l)
Moderate < 2 risk factors and Pol-SCORE risk < 10% < 100 mg/dl
(< 2.6 mmol/l)
Low No additional risk factors <115 mg/dl
(< 3.0 mmol/l)
LDL-C: low-density lipoprotein cholesterol; SCORE: Systematic COronary Risk Evaluation
trial, the PCSK9 inhibitor evolocumab combined with 
a statin reduced the incidence of cardiovascular events 
in patients with the atherosclerotic circulatory disease, 
as compared to the treatment with statins alone [38]. 
Similar results were achieved in the subgroup of patients 
with LEAD, for whom evolocumab reduced the cardi-
ovascular mortality and the risk of heart attack, stroke, 
hospitalization due to angina, or the need for coronary 
revascularization [39]. Furthermore, treatment with 
evolocumab reduced the risk of adverse limb-related 
events (including amputations) by 42% compared to 
statins alone. 
The recommendations on hypolipidemic therapy in 
patients with LEAD are outlined in Table 5. 
5.1.2. Glycemic control in patients with lower  
extremity artery disease and diabetes
For patients with PAD and co-occurring diabetes, 
strict glycemic control is recommended according to 
the general standards [1, 40]. It is also believed that 
glycemic control is particularly important for improving 
the lower extremities treatment outcomes, including 
reducing the frequency of amputations in patients with 
critical limb ischemia and improving the patency after 
revascularization in the lower leg [41, 42]. 
According to the guidelines of the Polish Diabeto-
logical Association, the first-line drug for patients with 
type 2 diabetes is metformin (unless there are con-
traindications for use) [40]. Choosing the anti-diabetic 
medications, it should be taken into account that the 
benefit of reducing the cardiovascular risk has been 
confirmed for only a handful of those agents. The results 
of large randomized clinical trials published in recent 
years show a reduction of the overall and cardiovascular 
mortality by some GLP-1 receptor agonists (liraglutide 
among those available in Poland), and SGLT-2 inhibitors 
(empagliflozin) [40]. It appears that the most beneficial 
effects were achieved with empagliflozin which signif-
icantly reduced the overall mortality, cardiovascular 
mortality and morbidity (overall mortality caused by 
cardiovascular disorders, heart attack and stroke), and 
the risk of hospitalization due to heart failure [43]. In the 
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recently published review of the results of EMPA-REG 
OUTCOME trial it was shown that in patients with 
type 2 diabetes and co-occurring PAD, empagliflozin 
reduced the cardiovascular mortality by 43% and 
overall mortality by 38% [44]. 
The recommendations on the treatment of diabetes 
in patients with LEAD are outlined in Table 5. 
5.1.3. Hypotensive therapy in patients with lower 
extremity artery disease
Arterial hypertension as a risk factor  
of the peripheral artery disease
Arterial hypertension is one of the key risk factors 
of atherosclerosis and its complications. The analy-
sis of causes of death provided in the World Health 
Organization’s report shows that AH is responsible 
for one-seventh of the overall mortality [45]. Similar 
conclusions have been formulated from the prospective 
epidemiological observations of over 8 million patients 
from around the world, conducted under the Global 
Burden of Disease study [46]. 
Globally, arterial hypertension affects around 30% 
of the adult population. In Poland, data from subse-
quent editions of NATPOL study show that the current 
number of patients exceeds 10 million; if the growth 
tendency is maintained, the population might increase 
by 50% over the next decade [47]. 
In the population of patients with abnormal ABI, 
the percentage of patients with AH is 60% (Rotterdam 
Study) [48]; similarly, in patients with arterial hyperten-
sion, lower ABI values are observed [49]. The risk of 
LEAD symptoms, such as intermittent claudication, is 
doubled in patients with AH than in normotensive pa-
tients [50] and usually affects untreated patients, or pa-
tients with insufficient arterial hypertension control [51]. 
Among all complications of atherosclerosis, PAD 
appears to be most closely related to the pulse pres-
sure; each increase of systolic pressure by 20 mm Hg 
increases the risk of PAD by 63%. [52].
Next to smoking, arterial hypertension is the main 
PAD progression factor; however, there is insufficient 
data to confirm that arterial blood pressure control 
would affect the progression of lesions in the peripheral 
arteries [53]. 
Pharmacotherapy of arterial hypertension in patients 
with lower extremity artery disease
Reducing the arterial blood pressure reduces the risk 
of cardiovascular complications in patients with PAD. 
In the clinical trials on the efficacy of hypotensive 
therapy, the patients with PAD were a small group, 
but the available data indicate that they benefit from 
the therapy similarly to other groups [54]. Hence, the 
current guidelines recommend similar management 
of patients with PAD as other groups of patients with 
arterial hypertension [1, 55]. In the ESC guidelines, 
the recommended target arterial blood pressure for 
patients with PAD and AH is < 140/90 mm Hg (class 
of recommendation Ia) [1]. On the basis of the results 
of INVEST trial, in which 12% of the population was 
diagnosed with PAD, it is not recommended to reduce 
the systolic blood pressure below 110–120 mm Hg due 
to the potential increase of the cardiovascular risk [56]. 
In elderly patients with frailty syndrome, it is rec-
ommended to reduce the arterial blood pressure in 
a careful and gradual manner, controlling the patients for 
orthostatic hypotension, and the aforementioned target 
arterial blood pressure levels should be achieved only if 
they are well tolerated by the patients and do not cause 
excessive pressure drop in standing position [57, 58]. 
An important element of the management of this 
patient group is the change of lifestyle (quitting smoking, 
physical exercise, body weight reduction, reduction of salt 
intake to < 5–6 g/day). All classes of hypotensive drugs 
are used in treating arterial hypertension in patients with 
PAD. As first-line drugs in monotherapy or combined 
therapy, diuretics, beta-adrenolytics, calcium antagonists, 
angiotensin-converting-enzyme inhibitors (ACEI) and angi-
otensin receptor blockers (ARB) can be used. The choice 
of the hypotensive drug may depend on comorbidities 
and co-occurring clinical conditions. The European and 
American guidelines [1, 2] state that for patients with PAD, 
ACEI or ARB should be considered as first-line drugs (class 
of recommendation IIa). The preference for renin-angio-
tensin system inhibitors arises from the data acquired in 
HOPE and ONTARGET trials which showed that ramipril 
or telmisartan reduced the cardiovascular risk in patients 
with PAD [59, 60]. Those drugs were also beneficial to 
patients with advanced ischemia (chronic limb-threatening 
ischemia, CLTI). In this patient group, treatment with ACEI 
or ARB reduced the incidence of major cardiovascular 
events and mortality, without affecting the outcomes of 
limb ischemia treatment [61]. 
Patients with PAD often have absolute indications 
for treatment with beta-adrenolytics, such as a histo-
ry of heart attack or heart failure with impaired left 
ventricular contractile function. In the observational 
study, treatment of patients after myocardial infarction 
with beta-adrenolytics significantly reduced the risk of 
coronary events by 53% [62]. Using drugs from this 
class did not affect the claudication distance in patients 
with mild or moderate LEAD [63]. However, caution is 
recommended when using those drugs in patients with 
critical ischemia, despite the fact that in the observa-
tional studies, even in patients with CLTI the clinical 
outcomes of treatment were non-inferior among the 
patients treated with beta-adrenolytics to patients not 
receiving those drugs [64, 65].
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Data on the beneficial effect of hypotensive drugs on 
intermittent claudication symptoms (walking distance) in 
patients with LEAD are limited. The ESC guidelines [1] 
state that, given the impact on intermittent claudication, 
calcium antagonists or ACEI/ARB are preferred for pa-
tients with PAD and arterial hypertension, due to their 
ability to dilate peripheral arteries. A randomized clinical 
trial showed that verapamil extended the walking dis-
tance in patients with LEAD [66]. Similar benefits were 
achieved in one randomized trial with ramipril [67]. 
The results of trials using ACE inhibitors are controver-
sial, since of the six trials with ACE inhibitors compared 
to placebo which was included in the meta-analysis in 
2013 [68], an improvement in the walking distance 
was observed in three trials with ramipril, two of 
which were subsequently retracted due to unreliable 
data [69], while three trials with other ACE inhibitors 
(captopril, cilazapril, perindopril), no benefits were 
achieved. In the new meta-analysis, which included 
only the four trials remaining after the two studies on 
ramipril had been retracted, no improvement of the 
walking distance was found [70]. 
 Nebivolol was also hailed as a beta-adrenolytic 
drug with additional vasodilatory action [1], but the 
evidence of the potential superiority of vasodilatory 
beta-adrenolytics over the conventional beta-adrenalitis 
in patients with LEAD is very limited. Metoprolol and 
nebivolol were compared in a double-blind randomized 
clinical trial with 128 adrenolytic treatment-naïve 
patients suffering from intermittent claudication and 
arterial hypertension [71]. After 48 weeks of treatment, 
both drugs were found to be well-tolerated, exercising 
similar hypotensive effect and improving the maximum 
walking distance and ABI in both groups, without sig-
nificant differences between the groups. Nebivolol was 
found to be superior only in terms of improving the 
walking distance until pain occurred. 
The recommendations on the treatment of arterial 
hypertension in patients with LEAD are outlined in 
Table 5. 
5.2. Anticoagulation treatment
Anticoagulation treatment is an important aspect of 
pharmacotherapy in patients with LEAD, aimed at both 
reducing the global cardiovascular risk and the risk of 
limb-related incidents, and improving the treatment 
outcomes after percutaneous or surgical revascular-
ization. 
Platelets play a crucial role in the pathogenesis of 
atherosclerotic and thrombotic complications in the 
arterial system, and the inhibition of platelet activation 
and aggregation is the basic mechanism of prevention 
of adverse cardiovascular events. The antiplatelet agent 
of choice is acetylsalicylic acid (ASA) which inhibits 
cyclooxygenase activity and thromboxane A2 synthe-
sis. Other antiplatelet drugs include platelet P2Y12 
receptor inhibitors which inhibit ADP-induced platelet 
activation, thienopyridine derivatives (ticlopidine, later 
replaced with clopidogrel and prasugrel), and ticagre-
lor which unlike clopidogrel is a non-thienopyridine, 
reversible inhibitor of the P2Y12 receptor. Among the 
currently used P2Y12 receptor inhibitor, large trials on 
patients with LEAD studied clopidogrel and ticagrelor, 
while prasugrel has thus far been studied mainly in 
patients with coronary artery disease. The new oral 
antiplatelets are PAR-1 thrombin receptor antagonists 
(e.g. vorapaxar and atopaxar) which inhibit thrombin-in-
duced platelet activation [72]. Among those agents, 
vorapaxar was studied in large clinical trials on patients 
with LEAD. PAR-1 thrombin receptor antagonists are 
currently not available in Poland.
Anticoagulation drugs, including vitamin K antago-
nists (VKAs; warfarin and acenocoumarol) and direct 
oral anticoagulants (DOACs) other than vitamin K 
antagonists, are used mainly in patients with conven-
tional indications for chronic oral anticoagulation, such 
as acenocumarol or venous thromboembolism; how-
ever, data from the recent clinical trials also indicate 
a potential role of rivaroxaban combined with ASA 
in a broader population of patients with LEAD, who 
do not have conventional indications for chronic oral 
anticoagulation. 
Various anticoagulation therapy strategies are avail-
able, but the choice between specific strategies is not 
always clear [73]. The key international guidelines differ 
slightly in terms of indication for treatment and the 
choice of specific drugs [1-3]. Furthermore, no single 
strategy will be optimal for all disease stages and pa-
tient subgroups (i.e. asymptomatic LEAD, intermittent 
claudication, critical limb ischemia, patients after intra-
vascular or surgical revascularization). In part due to 
those discrepancies and ambiguities, the anticoagulation 
treatment remains underused in patients with LEAD 
despite the high risk of atherosclerotic and thrombotic 
events in this patient group [73]. 
5.2.1. Asymptomatic lower extremity  
artery disease
In two randomized, placebo-controlled clinical trials, 
no benefits were found from using ASA in asympto-
matic LEAD [74, 75]. One of the trials was conducted 
in a general population with ABI < 0.95, the other in 
a population of diabetic patients with ABI < 1.0. No 
benefits from using ASA were also found in subgroups 
with ABI < 0.9, although those studies might not have 
had the sufficient statistical power to detect benefits 
from using ASA in patients with lower ABI values 
[73]. On the basis of the results of those trials, the 
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ESC guidelines on the management of PAD [1] stated 
that antiplatelet therapy is indicated for patients with 
symptomatic LEAD or after revascularization (class of 
recommendation/level of evidence: I A/C), but is not 
routinely indicated in patients with asymptomatic LEAD 
who do not have indications for antiplatelet therapy 
due to another arterial disease (e.g. coronary artery 
disease). Authors of other guidelines believe, however, 
that antiplatelet therapy should be considered also for 
patients with asymptomatic LEAD (ABI ≤ 0.9), given the 
generalized nature of atherosclerosis and high cardio-
vascular risk in those patients (class of recommendation/ 
/level of evidence: IIa/C in 2016 AHA/ACC guidelines) 
[2]. Given the absence of evidence of the benefits of 
antiplatelet therapy in patients with asymptomatic 
LEAD, it is also unclear whether patients with masked 
LEAD (see 3.2) should be classified as patients with 
asymptomatic or symptomatic disease.
5.2.2 Symptomatic lower extremity artery disease
Single antiplatelet drug therapy
Acetylsalicylic acid — it is believed that the strongest 
evidence of the benefits of using ASA in symptomatic 
LEAD has been provided by the Antithrombotic Trialists 
Collaboration meta-analysis which showed that in 6, 
200 patients with intermittent claudication, taking ASA 
significantly reduced the incidence of major adverse 
cardiovascular events (MACE; cardiovascular deaths, 
and non-fatal myocardial infarction and stroke), as 
compared to the control group [76]. Also, in the later 
randomized CLIPS trial which enrolled patients with 
asymptomatic LEAD or intermittent claudication (n = 
366, 77% of patients with intermittent claudication), us-
ing ASA significantly reduced the incidence of MACE or 
critical limb ischemia [77]. However, some meta-anal-
yses did not find significant benefits from using ASA in 
patients suffering mainly from symptomatic PAD [78]. 
Clopidogrel — in the post hoc analysis of the data 
from CAPRIE trial, it was found that in the subgroup of 
6,452 patients with clinically overt LEAD clopidogrel 
significantly reduced cardiovascular mortality and the 
incidence of MACE as compared to ASA [79]. Indirect 
comparisons of various regimens using the meta-anal-
ysis of clinical trials also show the superiority of clopi-
dogrel over ASA [80]. Based on the data from CAPRIE 
trial, the ESC guidelines considered clopidogrel to be 
more preferable than ASA, however, with a low class 
of recommendation and level of evidence (IIb/B) [1], 
while the other major international guidelines [2, 3] 
do not prefer clopidogrel over ASA as the antiplatelet 
drug of choice for symptomatic LEAD monotherapy.
Ticagrelor — the randomized EUCLID trial com-
pared ticagrelor with clopidogrel in 13, 885 patients 
with symptomatic LEAD, finding no difference in the 
incidence of MACE or major bleeding [81]. Treatment 
with ticagrelor was related to a significantly higher in-
cidence of stroke, and also more frequent termination 
of treatment. 
Dual antiplatelet therapy
It is believed that there is no direct evidence of the 
superiority of dual antiplatelet therapy (DAPT) with 
clopidogrel and ASA over ASA alone in patients with 
LEAD [82]. Dual antiplatelet therapy with clopidogrel 
and ASA was compared to ASA alone in CHARISMA 
trial. In the subgroup of patients with LEAD, using 
DAPT reduced the incidence of myocardial infarction, 
without affecting the overall incidence of MACE, and 
also increased 2-fold the incidence of minor bleeding, 
without affecting the incidence of major, fatal and mod-
erate bleeding [83]. 
The comparison of PAR-1 thrombin receptor antag-
onist vorapaxar with placebo (in both groups, in com-
bination with standard antiplatelet therapy) in the sub-
group of patients with symptomatic LEAD in TRACER 
trial failed to demonstrate a significant reduction of the 
incidence of ischemic events, peripheral revasculariza-
tion and amputations by that antiplatelet agent [84]. In 
larger TRA2ºP-TIMI 50 trial, in the subgroup of patients 
with symptomatic LEAD, vorapaxar failed to reduce 
the risk of MACE but significantly reduced the risk of 
acute limb ischemia and peripheral revascularization as 
compared to placebo (in both groups in combination 
with standard antiplatelet therapy), however, at the 
cost of the increased bleeding risk [85, 86].
Dual antiplatelet therapy in patients with lower 
extremity artery disease and co-occurring  
coronary artery disease
The co-occurrence of LEAD and coronary artery dis-
ease is related to worse prognosis, and the presence of 
LEAD in patients might be an argument for a prolonged 
DAPT. In PRODIGY trial, which compared different 
durations of DAPT (clopidogrel and ASA) after coro-
nary artery stenting, DAPT prolonged to 24 months 
reduced the risk of MACE in the subgroup of patients 
with co-occurring LEAD, as compared to a 6-month 
DAPT; however, for the entire group, no evidence of 
superiority of prolonged DAPT was found [87, 88]. 
PEGASUS–TIMI 54 trial assessed prolonged use of tica-
grelor in the dose of 90 mg or 60 mg bid, combined with 
a low dose of ASA, in stable patients who had suffered 
from a myocardial infarction (1–3 years prior) [89]. In 
the subgroup of patients with the concomitant LEAD, 
ticagrelor was most beneficial in terms of reducing the 
incidence of MACE, and also significantly reduced the 
risk of major adverse events in the limb (acute limb 
ischemia and peripheral revascularization) [90]. The 
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ESC guidelines on the management of PAD [1] state 
that long-term treatment with ticagrelor combined 
with low-dose ASA may be considered in patients with 
LEAD who had suffered from a myocardial infarction 
more than 3 years prior (no class of recommendation 
specified). 
Both the long-term use of ticagrelor combined 
with ASA after a heart attack in PEGASUS–TIMI 54 
trial, and the prolonged DAPT with clopidogrel and 
ASA after acute coronary syndrome and/or coronary 
artery stenting, increased the incidence of major 
bleeding [89, 91]. The decision on prolonging DAPT 
must include a careful assessment of the risk of both 
ischemic events and bleeding. The duration of DAPT in 
patients with coronary artery disease and concomitant 
LEAD, who are receiving DAPT for acute coronary 
syndrome and/or percutaneous coronary intervention, 
should generally conform to the current guidelines on 
DAPT [92]. 
Combined antiplatelet and anticoagulation therapy
Conventional anticoagulation therapy does not play an 
important role for patients with symptomatic LEAD 
who have no other confirmed indications for such 
treatment, such as atrial fibrillation or venous throm-
boembolism. The efficacy of warfarin or acenocumarol 
(with the target values of the international normalized 
ratio [INR] of prothrombin time of 2.0–3.0) combined 
with antiplatelet therapy, as compared to antiplatelet 
therapy alone in patients with PAD was assessed by 
WAVE trial. The trial failed to demonstrate the superi-
ority of the combined antiplatelet and anticoagulation 
therapy in terms of MACE prevention; on the other 
hand, this type of treatment increased 3-fold the inci-
dence of life-threatening bleeding [93]. An interesting 
therapeutic option is combining antiplatelet therapy 
with small doses of new oral anticoagulants. The first 
observations suggesting a beneficial effect of this kind 
of combined treatment originate from the studies on 
the subgroups of patients who suffered from acute 
coronary syndrome and received small doses of new 
oral anticoagulants in addition to antiplatelet therapy 
(ATLAS ACS 2 TIMI 51 trial) [94].
The recent COMPASS trial assessed the new strate-
gy of combined antiplatelet and anticoagulation therapy 
based on combining ASA with a small dose of DOAC, 
which was compared to the use of ASA alone and 
NOAC alone in patients with confirmed stable circula-
tory disease [95]. Since the results of COMPASS trial 
suggest new opportunities for combined anticoagulation 
therapy in patients with LEAD; because those results 
could not have been included even in the latest 2017 
ESC guidelines on the management of PAD, the authors 
of this document have decided to discuss them in detail 
herein due to their potential impact on the future prac-
tice of management of patients with LEAD. 
COMPASS trial
COMPASS was a large, multi-centre, randomized trial 
which compared the combined treatment with ASA 
(100 mg/day) and small dose of rivaroxaban (2.5 mg 
bid), and rivaroxaban alone (5 mg bid) or ASA alone 
(100 mg/day), in over 27,000 patients with stable cor-
onary artery disease or PAD. The trial was terminated 
after an average of 23 months of observation due to the 
superiority of the combined treatment with ASA and 
rivaroxaban which significantly reduced the incidence 
of the composite endpoint of cardiovascular deaths, 
myocardial infarctions and strokes, and the reduction 
of cardiovascular mortality and overall mortality [95].
In the prospectively planned analysis of a subgroup 
of 7,470 patients with PAD (LEAD or carotid artery 
disease) it was determined that the combined treat-
ment with ASA and rivaroxaban significantly reduced 
the incidence of the aforementioned composite end-
point, as compared to ASA alone (reduction of risk by 
28%), and significantly reduced the incidence of major 
limb-related events, including amputations (reduction of 
risk by 46%) [96]. The overall risk of amputations due 
to vascular causes was reduced by 60%, and the risk 
of major amputations was reduced by 70% compared 
to the group treated with ASA only. The median treat-
ment period was 21 months. The inclusion criteria for 
patients with LEAD included: previous percutaneous or 
surgical intervention, history of amputation, or inter-
mittent claudication in patients with objectively docu-
mented LEAD (ABI < 0.9 or arterial stenosis ≥ 50%). 
Major limb-related incidents were defined as acute 
limb ischemia, severe chronic limb ischemia requiring 
vascular intervention, or amputation. The results in the 
subgroup with LEAD were similar to the entire group 
of patients with PAD. Monotherapy with rivaroxaban 
failed to reduce the incidence of the primary endpoint 
compared to ASA but reduced the incidence of major 
limb-related incidents, as well as the incidence of am-
putations. Rivaroxaban, both in monotherapy and in 
combination with ASA, increased the incidence of major 
bleeding, mainly from the gastrointestinal tract, but no 
increase of the incidence of fatal bleeding, intracranial 
hemorrhages and within the major organs.
Also, the results of a separate analysis were pub-
lished concerning the incidence of major limb-related 
events in 6, 391 patients with LEAD who were enrolled 
in COMPASS trial [97]. Compared to the treatment 
with ASA alone, the combined treatment with ri-
varoxaban and ASA reduced the incidence of major 
limb-related events by 43%, all amputations by 59% 
and peripheral vascular interventions by 24%. The oc-
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currence of a major limb-related event was related to 
poor prognosis (8.3% risk of death within 1 year; 20.5% 
risk of amputation within 1 year). The benefits of treat-
ment with rivaroxaban were offset by the increased 
risk of major bleeding, although without a significant 
increase in the incidence of severing and fatal bleeding. 
The authors of the editorial note [98] pointed out that 
due to the fact that the absolute reduction of the risk 
of major limb-related events was more or less equal 
to the absolute increase of the risk of major bleeding, 
the assessment of the benefits to risk ratio related to 
the addition of rivaroxaban might be difficult. The risk 
of major limb-related events was highest in patients 
with a history of amputations or vascular interventions 
(3.8%), followed by patients with symptomatic LEAD 
but without prior amputations or vascular interventions 
(1.73%). The lowest risk was observed for patients 
with asymptomatic LEAD (0.5%). Thus, it appears that 
the benefits to risk ratio may be most favourable for 
patients with a history of prior amputations and vascular 
intervention, and the least favourable for patients with 
asymptomatic LEAD. Given the overall reduction of the 
risk of MACE in COMPASS trial, it was also concluded 
that the addition of rivaroxaban may be more beneficial 
to patients with concomitant coronary artery disease, 
especially those who had a previous heart attack.
5.2.3. Patients with lower extremity artery disease 
who underwent intravascular or surgical  
peripheral revascularization
Antiplatelet and anticoagulation therapy after  
surgical revascularization of LEAD
Acetylsalicylic acid compared to placebo — the 
meta-analysis (952 patients) revealed that the patency 
of the peripheral bypass was significantly improved in 
the ASA group compared to placebo. The beneficial 
therapeutic effect was particularly visible for bypasses 
made with synthetic materials. The incidence of ampu-
tations and bleeding and the survival rate were similar 
regardless of whether ASA was used or not [99].
Acetylsalicylic acid compared to oral anticoagu-
lants — using VKAs after surgical bypassing of peripher-
al arteries is not well established in the clinical practice. 
In the trial titled “Dutch Bypass Oral Anticoagulants or 
Aspirin Study”, a 2-year observation failed to demon-
strate differences in the patency of the bypasses, mor-
tality and incidence of amputations between the group 
receiving ASA (or ASA and dipyridamole) and the group 
receiving VKAs. The analysis of subgroups revealed, 
however, that in the group with a venous bypass, 
VKAs prolonged the patency of the bypass. The major 
bleeding risk was 2 times higher among the patients 
receiving VKAs [100]. Another study showed that com-
bined therapy with VKA and ASA in the post-operative 
period did not significantly impact the patency of the 
bypasses as compared to the patient group receiving 
only ASA, but increased the major bleeding risk 2-fold. 
The only group who benefited from the combined 
VKA+ASA therapy were the patients who had had 
a synthetic bypass with 6 mm diameter implanted. The 
benefit was not observed in patients with the bypass with 
8 mm diameter [101]. Also, the use of dalteparin com-
bined with ASA failed to benefit the patients who had 
undergone surgical revascularization due to LEAD [102]. 
The benefits from using warfarin and ASA compared 
to ASA alone were observed in a small study on pa-
tients with venous bypasses who were in the high 
bypass occlusion risk group (suboptimal bypass, poor 
reception of blood from the bypass, reoperation). The 
combined treatment was also related to increased 
incidence of bypass patency and limb preservation but 
at the cost of increased incidence of hematomas [103]. 
DAPT was also assessed in comparison to the com-
bined treatment with VKAs and clopidogrel in patients 
who had undergone femoral-popliteal bypass surgery. 
A significant difference was found in the patency of the 
bypasses in favour of the patients treated with VKAs 
and clopidogrel; the incidence of MACE did not differ 
between the groups. Also, in that study, the use of VKAs 
increased the incidence of bleeding [104]. 
Acetylsalicylic acid compared to dual antiplatelet 
therapy — the randomized trial CASPAR compared 
monotherapy (with ASA) with DAPD (ASA + clopi-
dogrel) in patients who had undergone bypass and 
peripheral shunt surgery below the knee joint. No 
differences were found between the groups in terms 
of the incidence of the composite endpoint of bypass 
occlusion, repeated revascularization, limb amputation 
above the knee joint, and death. A beneficial therapeutic 
effect of DAPT in terms of the endpoint specified above 
was found only in the prospectively defined subgroup of 
patients who had undergone femoral-popliteal bypass 
surgery with a synthetic bypass; no such benefits were 
found in patients with venous bypasses. At the same 
time, increased bleeding incidence was observed in 
the DAPT group, although the incidence of sever and 
fatal bleeding did not differ significantly between both 
groups [105].
Antiplatelet/anticoagulation therapy after  
intravascular interventions due to LEAD
Not much data is available on the efficacy and safety of 
various anticoagulation treatment regimens in patients 
who undergo intravascular interventions for LEAD. 
The current standard regimens after intravascular 
interventions in peripheral arteries are partially based 
on the results of studies assessing the regimens after 
coronary interventions.
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Currently, the guidelines recommend DAPT for 
at least 1 month after the intravascular intervention, 
regardless of the stent type (uncoated metal stent or 
drug-eluting stents) [1, 3]. In clinical trials, DAPT is 
typically administered for at least 30-60 days, also in 
studies with drug-coated balloons [106, 107], although 
sometimes it is used for much longer periods — for 
example, in IN. PACT SFA study, in half of the enrolled 
patients DAPT was continued for over a year [108]. 
As specified in the ESC guidelines [1], DAPT is often 
administered longer after stenting arteries below the 
knee, but there is no evidence to support this strategy. 
Once DAPT is ended, regardless of its duration, the 
standard procedure after an intravascular intervention 
is indefinite treatment with a single antiplatelet agent 
(ASA or clopidogrel).
In MIRROR study, it was found that the use of clopi-
dogrel and ASA for 6 months reduced the frequency 
of repeated interventions as compared to ASA alone, 
but that benefit of DAPT was not maintained after 
6 months from discontinuing clopidogrel (i.e. after 
a total of 12 months of observation). The authors of the 
study concluded that for the patients who are in a high 
restenosis risk group, who would potentially benefit 
most from a prolonged DAPT, long-term treatment 
may be considered (> 6 months); currently, decisions 
on prolonging DAPT are often made on a case-by-case 
basis [109]. Prolonging DAPT may also be considered 
in the event of a coronary artery disease co-occurring 
with LEAD (see above). The ESC guidelines on the 
management of PAD [1] state that in patients with LEAD 
who have undergone percutaneous revascularization 
below the groin, DAPT may be prolonged to more than 
1 month if the patient previously (i.e. within the previ-
ous year) suffered from acute coronary syndrome and/
or underwent percutaneous coronary intervention, and 
also after stenting the last patent coronary artery, and 
in the event of a multi-vessel coronary artery disease 
with incomplete revascularization in diabetic patients.
Anticoagulants do not play any role in patients after 
intravascular interventions due to LEAD. Anticoagula-
tion therapy was analyzed prospectively after percu-
taneous revascularization below the groin, finding no 
improvement of vascular patency, while the incidence 
of bleeding was significantly increased [110].
5.2.4. Summary — choosing the anticoagulation 
strategy
The anticoagulation therapy options for patients with 
LEAD can be divided into three main clinical categories: 
asymptomatic patients (ABI ≤ 0.9, without intermit-
tent claudication), symptomatic patients (intermittent 
claudication), or patients undergoing intravascular or 
surgical revascularization. The main clinical trials related 
to anticoagulation therapy of patients with LEAD are 
summarized in Figure 1, while the proposed strategies 
of management are illustrated in Figure 2. 
The recommendations on anticoagulation therapy 
of patients with atherosclerotic LEAD, without sepa-
rate indications for chronic oral anticoagulation, are 
outlined in Table 8.
Asymptomatic lower extremity artery disease
In this patient group, treatment with the only single 
antiplatelet drug should be considered (ASA or clopi-
dogrel). No clear evidence of the benefits of using ASA 
compared to placebo have been obtained in patients 
with asymptomatic LEAD, hence the difference of 
opinion between the experts on the indications for 
antiplatelet treatment in this group. The ESC guide-
lines do not recommend using antiplatelet agents in 
this group (class of recommendation/level of evidence: 
III/A) [1], while the 2016 AHA/ACC guidelines state 
that antiplatelet therapy is reasonable also in patients 
with asymptomatic LEAD (class of recommendation/ 
/level of evidence: IIa/C for patients with ABI ≤ 0.9) 
[2]. This opinion was reiterated in more recent studies 
by American experts [73]. Treatment with ASA may 
be considered especially in patients with co-occurring 
atherosclerotic lesions in other arterial beds. Indica-
tions for treatment with ASA may also arise from the 
co-occurring symptomatic coronary artery disease, 
or cerebrovascular disease (history of brain stroke or 
transient ischemic attack [TIA]).
Symptomatic lower extremity artery disease
In this patient group, antiplatelet therapy is clearly 
recommended (class of recommendation I in all major 
guidelines) to reduce the risk of cardiovascular events. 
Treatment with only one antiplatelet agent may be 
considered, choosing between ASA or clopidogrel; 
recently, in view of the results of COMPASS trial, also 
combined anticoagulation therapy with ASA and a small 
dose of rivaroxaban may also be put into consideration. 
On the basis of the data from CAPRIE study, which 
found that clopidogrel was more beneficial than ASA to 
patients with LEAD, the authors of ESC guidelines [1] 
have concluded that clopidogrel may be the drug of 
preference (class of recommendation/level of evidence: 
IIb/B); this opinion was shared by the authors of other 
guidelines: in the 2016 ACC/AHA guidelines [2], both 
drugs have identical class of recommendation/level of 
evidence (I/A), and the 2015 guidelines of the Society 
of Vascular Surgery [3] also do not specify preference 
for clopidogrel (ASA — I/A, clopidogrel as an alternative 
agent — I/B).
On the basis of the result of COMPASS study, 
an alternative strategy for anticoagulation treatment 
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in this group may be based on ASA combined with 
a small dose of rivaroxaban. Given the reduction of the 
MACE risk, both clopidogrel in CAPRIE study and the 
combination of ASA and a small dose of rivaroxaban 
in COMPASS study proved more efficient in patients 
with LEAD than ASA alone. However, a reduction of 
the risk of major adverse events in the limb, including 
amputation, was observed only for the combination of 
ASA and a small dose of rivaroxaban; there is no evi-
dence of the similar effect of ASA or clopidogrel alone. 
The absolute reduction of the risk of MACE and major 
adverse events in the limb in COMPASS study was 
1.54% per year (NNT 58) [73], whereas the absolute 
reduction of the risk of MACE in CAPRIE study was 
1.15% per year (NNT 87) [79]. However, there is no 
direct comparison available between the small dose 
of rivaroxaban (± ASA) and clopidogrel in patients 
with LEAD. Taking into consideration the increase of 
the major bleeding risk, the absolute reduction of the 
composite incidence of MACE, major adverse events 
in the limb, fatal bleeding and symptomatic bleeding 
within the major organs (net clinical benefit) in COM-
PASS trial was 1.43% per year (NNT 70) [73]. In the 
CAPRIE study, clopidogrel proved safer than aspirin in 
terms of bleeding [79]. Considering the use of ASA and 
a small dose of rivaroxaban in patients with symptomatic 
LEAD, the bleeding risk must be weighed carefully, all 
the more so that the patients in the high bleeding risk 
group were excluded from COMPASS study. Summing 
up, it appears that both strategies (clopidogrel and the 
combination of ASA and a small dose of rivaroxaban) 
may be considered as potentially more beneficial than 
ASA alone in patients with symptomatic LEAD. 
Other possible anticoagulation strategies are not 
relevant for this patient group. Ticagrelor is not rec-
ommended, since in EUCLID study it did not prove 
superior to clopidogrel. Similarly, there are no indi-
cations for DAPT in patients who do not undergo 
revascularization due to LEAD, because CHARISMA 
study failed to demonstrate a clear superiority of the 
combined treatment with clopidogrel and ASA over 
single antiplatelet regimen. Vorapaxar is not available in 
Poland, since according to the clinical trials conducted 
thus far, vorapaxar’s value when combined with stand-
ard antiplatelet therapy remains unclear and requires 
further study (in TRA2ºP–TIMI 50 study, a reduction 
Figure 1. Main clinical trials related to anticoagulation therapy of patients with lower extremity artery disease [73]
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Figure 2. Anticoagulation strategies for patients with lower extremity artery disease (modified according to [1, 73])
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of the risk of acute limb ischemia and the incidence of 
peripheral revascularizations was shown, but at the 
cost of increased bleeding risk and without impact on 
MACE). Conventional anticoagulation therapy (with 
VKAs or NOACs in standard dosing regimens) should 
not be used to reduce the risk of cardiovascular/is-
chemic events in this patient group since no evidence 
was found of the benefits of such treatment [2, 3, 93]. 
Patients with LEAD and concomitant coro-
nary artery disease — a separate group is formed 
by the patients with a history of the recent acute 
coronary syndrome and/or percutaneous coronary 
intervention, which should be treated with DAPT 
with clopidogrel or ticagrelor and ASA. The indication 
for DAPT arises from coronary artery disease, rather 
than LEAD. The previous standard therapy involved 
clopidogrel and ASA. In the current ESC guidelines 
on the management of patients with ACS, the newer 
P2Y12 receptor inhibitors (ticagrelor and prasugrel, 
and only ticagrelor in patients undergoing conservative 
treatment) are preferred over clopidogrel [92]. On 
the basis of the results of PEGASUS–TIMI 54 study, 
long-term treatment with ticagrelor combined with 
a small dose of ASA may be considered for patients 
with LEAD after a history of myocardial infarction 
less than 3 years prior [1]. For patients with LEAD, 
prolonged DAPT may also be considered after acute 
coronary syndrome and/or stenting of coronary ar-
teries. However, both strategies involve an increased 
risk of major bleeding, hence a careful assessment is 
necessary for the risk of both ischemic events and 
bleeding (Table 9). The duration of DAPT in patients 
with coronary artery disease and concomitant LEAD, 
who are receiving DAPT for acute coronary syndrome 
and/or percutaneous coronary intervention, as well as 
the choice of the P2Y12 receptor inhibitor (ticagre-
lor or clopidogrel), should generally conform to the 
current guidelines on DAPT [92]. Following the com-
pletion of DAPT, patients in this group receive a single 
antiplatelet drug (ASA or clopidogrel) indefinitely.
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Revascularization due to lower extremity  
artery disease
Surgical revascularization — for patients who 
have undergone surgical revascularization, various 
strategies may be considered, including a single anti-
platelet regimen (ASA or clopidogrel), DAPT, VKAs, and 
recently, given the results of COMPASS study, also the 
combined anticoagulation therapy with ASA and a small 
dose of rivaroxaban. Given the results of CASPAR study, 
it appears that for the entire population of patients who 
Table 8. Anticoagulation therapy (antiplatelet and antithrombotic) in patients with atherosclerotic lower extremity artery disease
Recommendation Class  
of recommendation
Level (quality) 
of evidence
Asymptomatic LEAD
Due to the lack of confirmed benefits, antiplatelet therapy is not routinely indicated  
for patients with isolated asymptomatic LEAD
III A
Symptomatic LEAD
Long-term SAPT is recommended for patients with symptomatic LEAD I A
Preference of clopidogrel over ASA may be considered IIb B
Instead of SAPT, a combined treatment with ASA and small dose of rivaroxabanb may  
be considered, especially in patients with high risk of ischemic events in the limbc,  
provided that the bleeding risk is low 
GPS
DAPT is not recommended in patients who are not undergoing revascularization for LEAD III B
Oral anticoagulants in therapeutic doses are not recommended in patients who are not  
undergoing revascularization for LEAD and who have no other indications for long-term 
oral anticoagulation therapy
III B
DAPT (ASA + clopidogrel or ticagrelor) may be considered in patients with LEAD  
who have indications for DAPT due to coronary artery diseased
IIb B
Patients who underwent revascularization for LEAD
Long-term SAPT is recommended for all patients who underwent revascularization I C
SAPT is recommended after surgical revascularization I A
VKAs may be considered (without antiplatelet therapy) after surgical revascularization  
in individual cases, especially in patients with venous bypasses, if the bleeding risk is low  
compared to the risk of bypass occlusion
IIb B
DAPT may be considered after surgical revascularization in patients with synthetic  
bypasses implanted below the knee
IIb B
DAPT (ASA + clopidogrel) should be considered for at least 1 month after intravascular 
revascularization
IIa C
A longer DAPT may be considered after intravascular revascularization in patients with  
a high risk of an ischemic event in the limbc
IIb B
After both surgical and intravascular revascularization, DAPT (ASA + clopidogrel or  
ticagrelor) may be considered in patients with LEAD who have indications for DAPT  
due to coronary artery diseased 
IIb B
After both surgical and intravascular revascularization, a combined treatment with ASA  
and a small dose of rivaroxabanb may be considered, especially in patients with a high risk 
of ischemic events in the limbc, provided that the bleeding risk is low
GPS
ASA: acetylsalicylic acid; DAPT: dual antiplatelet therapy; LEAD: lower extremity artery disease; SAPT: single antiplatelet therapy; VKA: vitamin K antagonist.
aIf there is no concomitant circulatory disease requiring antiplatelet therapy (e.g. coronary artery disease or a history of stroke/transient ischemic attack of the Central 
Nervous System)
bHigh risk of an adverse event in the limb can be defined as a synthetic bypass, bypass below the knee, suboptimal bypassing effect, poor blood reception from the 
bypass, widespread arterial lesions, or tissue loss [73]
cRecent acute coronary syndrome (ticagrelor is the preferred drug) and/or stenting of coronary arteries, heart attack < 3 years prior (ticagrelor is the preferred drug), 
status post-stenting of the last patent coronary artery, multi-vessel coronary artery disease in diabetic patients who have undergone incomplete revascularization
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Table 9. Risk factors of ischemic events, bleeding risk factors and increased risk factors for limbs which should be taken into 
consideration in making decisions on anticoagulation therapy in patients with atherosclerotic lower extremity artery disease [73]
Risk of ischemic events ≠ Bleeding risk ≠ Risk for limb ≠
History of heart attack Anticoagulation treatment Synthetic bypass
Diabetes History of bleeding Bypass below the knee
Old age Old age Suboptimal bypassing effect
Chronic kidney disease Chronic kidney disease Poor reception of blood from the bypass
Heart failure Anaemia Widespread arterial lesions
Smoking Low body weight Tissue loss
have undergone surgical revascularization, DAPT is not 
clearly superior over a single antiplatelet regimen. In the 
study, the benefits of DAPT were observed after bypass 
surgery below the knee in the patients with synthetic 
bypasses; no such benefits were found in patients with 
venous bypasses. The evidence of the benefits of VKA 
therapy is also limited and obtained mainly from patients 
with venous bypasses. 
The ESC guidelines [1] generally recommend single 
platelet regimen for this group (ASA or clopidogrel; 
class of recommendation/level of evidence I/A); alter-
native strategies include: 1) treatment with VKAs of pa-
tients with venous bypasses (class of recommendation/
level of evidence: IIb/B), although it is noted that the 
available evidence for anticoagulation therapy is weak 
and the bleeding risk increases twofold compared to 
antiplatelet agents; and 2) DAPT (ASA + clopidogrel) 
in patients with synthetic bypasses below the knee 
(class of recommendation/level of evidence: IIb/B). The 
authors of the guidelines also conclude that for patients 
with a history of recent acute coronary syndrome and/ 
/or percutaneous coronary intervention (less than 1 year 
prior), and after the stenting of the last patent coronary 
artery, and also in the case of multi-vessel coronary 
artery disease with incomplete revascularization in 
diabetic patients, DAPT may be considered [1]. Other 
major guidelines [2, 3] recommend single antiplatelet 
regimen (ASA or clopidogrel) or DAPT as an alternative; 
VKAs are either not recommended [3] or considered 
to be of uncertain usefulness [2]. 
In general, intensifying the anticoagulation therapy in 
this group should be considered firstly for the patients 
exposed to high risk of major adverse events in the 
limbs, such as bypass thrombosis or amputation. The 
risk factors related to the increased limb-related risk 
include synthetic bypass, bypass below the knee, the 
suboptimal effect of bypassing, poor blood reception 
from the bypass, widespread lesions in arteries, and 
tissue loss (Table 9) [73]. Among the three available 
strategies (ASA + small dose of rivaroxaban, DAPT 
or VKAs), the strongest evidence in terms of reducing 
the risk of major adverse events in the limbs of patients 
with LEAD have been acquired for the combined 
anticoagulation therapy with ASA and a small dose of 
rivaroxaban. This strategy has not yet been included 
in the major international guidelines, since the results 
of COMPASS study were published later, but can be 
found in the latest expert studies [73]. 
All regimens of the intensified anticoagulation ther-
apy are related to increased bleeding risk compared 
to the single antiplatelet regimen. Thus, a careful as-
sessment is necessary for the risk of both limb-related 
events and bleeding (Table 9). 
Intravascular revascularization (angioplasty with or 
without stenting)
The guidelines generally recommend DAPT (ASA + 
clopidogrel; ESC class of recommendation/level of 
evidence: IIa/C) for ≥ 1 month (1–6 months according 
to MIRROR study [73]); after DAPT is completed, the 
patients in this group are treated indefinitely with 
single antiplatelet regimen (ASA or clopidogrel), al-
though in light of the results of COMPASS study, also 
ASA combined with small dose of rivaroxaban may 
be considered. Prolonged DAPT may be considered 
for patients exposed to high risk of major adverse 
events in the limbs, and also in the case of indications 
arising from the concomitant coronary artery disease 
(e.g. recent history of the acute coronary syndrome 
and/or stenting of coronary arteries). The combined 
anticoagulation therapy with ASA and a small dose of 
rivaroxaban may also be more beneficial to patients 
in the group exposed to high risk of major adverse 
events in the limb. All regimens of the intensified 
anticoagulation therapy are related to increased 
bleeding risk. Thus, a careful assessment is necessary 
for the risk of both limb-related/ischemic events and 
bleeding (Table 9). 
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There is insufficient evidence to differentiate the 
recommendations on the anticoagulation treatment 
regimen depending on the intervention type (con-
ventional balloon angioplasty, drug-coated balloon 
angioplasty, metal stent implantation, drug-eluting stent 
implantation); the manufacturers’ recommendations 
generally favour longer DAPT for therapies based on 
pharmacological technology — however, the afore-
mentioned suggestions require confirmation in further 
studies on the revascularization of peripheral vessels. 
5.2.5. Antiplatelet and anticoagulation therapy in 
patients with lower extremity artery disease and 
separate indications for chronic oral anticoagula-
tion therapy
Patients with LEAD may have indications for chronic 
anticoagulation therapy arising from concomitant dis-
eases rather than from LEAD. A typical example is the 
co-occurrence of atrial fibrillation. LEAD is one of the 
risk factors of atrial fibrillation, and this type of arryth-
mia affects between 10% and 20% of patients with 
PAD [111–113]. The co-occurrence of LEAD and atrial 
fibrillation is related to worse prognosis [113, 114].
Few data are available on the choice of specific 
anticoagulation therapy in patients with LEAD and 
indication for oral anticoagulation therapy, it is gener-
ally recommended to treat such patients only with an 
oral anticoagulant, without antiplatelet drugs (class of 
recommendation/level of evidence: IIa/B in ESC guide-
lines) [1]. This applies to patients with symptomatic or 
asymptomatic LEAD, patients who have undergone 
surgical revascularization for LEAD, and patients who 
have undergone intravascular revascularization a long 
time before, or in the event of high bleeding risk. The 
ESC guidelines recommend that in such situations, the 
indication for chronic oral anticoagulation should be 
verified. Typical indications for anticoagulation include 
paroxysmal, persistent or permanent atrial fibrillation 
in patients with stroke risk factors, prosthetic heart 
valve or recent or recurrent venous thromboembolism 
(deep vein thrombosis and/or pulmonary embolism). In 
patients with LEAD and atrial fibrillation, anticoagulant 
is unequivocally recommended (class of recommenda-
tion/level of evidence: I/A) in patients with ≥ 2 score on 
CHA2DS2-VASc scale (congestive heart failure; arterial 
hypertension; age ≥ 75 — 2 points; diabetes, history 
of stroke or TIA — 1 point; vascular disease, including 
coronary artery disease or PAD; age 65–75, female sex), 
and should be considered (IIa/B) for all other patients. 
It should be emphasized that the presence of LEAD 
accounts for 1 point on CHA2DS2-VASc scale and may 
affect the indication for chronic oral anticoagulation. 
The decision to initiate an antiplatelet drug in patients 
who require long-term anticoagulation may depend on 
the concomitant coronary artery disease (recent acute 
coronary syndrome and/or percutaneous coronary 
intervention), or the need for intravascular revascular-
ization as part of LEAD management. Combined treat-
ment should be administered for the shortest possible 
time (at least 1 month is recommended), but decisions 
should be made on a case-by-case basis depending 
on the clinical indications and the bleeding risk [1]. 
In such situations, triple therapy (ASA, clopidogrel and 
anticoagulant) is advised against, with the exception of 
stenting arteries below the knee and complex lesions 
related to very high risk of thrombosis [1]. 
After intravascular revascularization, ASA or clopi-
dogrel combined with an oral anticoagulant for at least 1 
month should be considered, if the bleeding risk is low 
compared to the risk of stent/bypass occlusion (class 
of recommendation/level of evidence IIa/C in the ESC 
guidelines). After intravascular revascularization, only an 
oral anticoagulant should be considered if the bleeding 
risk is high compared to the risk of stent/bypass occlu-
sion (class of recommendation/level of evidence IIa/C 
in the ESC guidelines). An oral anticoagulant combined 
with a single antiplatelet drug for longer than 1 month 
may be considered in patients with high risk of ischemic 
events, or in the case of another strong indication for 
long-term antiplatelet therapy (class of recommenda-
tion/level of evidence: IIb/C; the ESC guidelines define 
it as prior stent thrombosis, acute limb ischemia dur-
ing treatment with oral anticoagulant, and indications 
arising from the concomitant coronary artery disease: 
recent acute coronary syndrome, stenting of the last 
patent coronary artery, multi-vessel coronary artery 
disease with incomplete revascularization in diabetic 
patients [1]). Based on the same indications, also 
a combination of an oral anticoagulant and a single an-
tiplatelet drug may be considered for patients from the 
group with high bleeding risk compared to stent/bypass 
occlusion risk. The proposed algorithm of management, 
based on the ESC guidelines [1], is illustrated in Figure 3. 
It is recommended to protect the stomach mucosa 
with a proton-pump inhibitor; the intensity of the oral 
anticoagulation must be carefully monitored. The target 
INR values for patients treated with VKAs is 2.0–2.5, 
with the exception of patients with the prosthetic mitral 
valve. Patients who receive NOACs combined with 
an antiplatelet drug should be treated with the lowest 
dose tested in the trials which have been the basis for 
the drug’s registration for stroke prevention [115, 116].
The recommendations on anticoagulation therapy 
of patients with atherosclerotic LEAD and separate 
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indications for chronic oral anticoagulation are outlined 
in Table 10.
5.3. Symptomatic treatment
For patients with intermittent claudication, the key 
elements of therapy are the prevention of cardiovas-
cular events and exercise training. If the patient’s daily 
activities are significantly disturbed, revascularization 
should be considered (combined with exercise therapy; 
this also applies to the situations when activity is signif-
icantly reduced despite the exercise therapy and other 
treatment methods). Pharmacotherapy to improve 
LEAD symptoms is only supplementary.
It should be pointed out that the drugs used to reduce 
global cardiovascular risk do not significantly improve 
intermittent claudication. For this reason, for patients 
with intermittent claudication, pharmacotherapy to 
improve the LEAD symptoms is often based on drugs 
other than used in reducing the cardiovascular risk. 
Statins are an exception since a number of meta-analy-
ses have shown a significant improvement of pain-free 
walking distance (PFWD) and maximum walking distance 
(MWD) in patients treated with statins [31, 117]. Statins 
can also reduce the incidence of adverse events in the 
legs of patients with LEAD [34]. Limited data indicating 
an improvement of the walking distance have also been 
acquired for hypotensive drugs (ramipril, verapamil) and 
antiplatelet drugs (details — see Table 3). 
It should also be emphasized that pharmacotherapy 
in intermittent claudication is not as efficient as exercise 
therapy or successful revascularization. The pharmaco-
therapy of intermittent claudication is also less efficient 
in patients who refuse to quit smoking and fail to adhere 
to exercise therapy. The objective of pharmacotherapy 
of claudication is to reduce the severity of LEAD symp-
toms and increase the walking distance for patients with 
intermittent claudication which affects the quality of 
life, particularly when modification of the risk factors 
and exercise therapy are unsuccessful and the patient 
is not eligible for revascularization, does not consent 
to such treatment, or there are contraindications for 
revascularization [1–3].
Figure 3. Anticoagulation therapy for patients with lower extremity artery disease who require chronic oral anticoagulation (mo-
dified according to [1]) 
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A number of pharmacological agents have been as-
sessed in the treatment of intermittent claudication of 
patients with LEAD. The most promising data, showing 
an increase in PFWD and MWD in randomized, con-
trolled clinical trials, were acquired for cilostazol and 
naftidrofuryl [118]; however, only the former is available 
in Poland. Other assessed agents, which have also been 
claimed to increase the walking distance in patients with 
intermittent claudication, include pentoxifylline, carni-
tine, propionyl-L-carnitine, prostanoids (prostaglandins I2 
and E2), buflomedil, L-arginine, maidenhair tree (Ginkgo 
biloba) and sulodexide [117–120]. The ESC guidelines 
on the management of patients with LEAD emphasize 
however that only limited objective documentation 
of the effect is available, and the beneficial impact on 
the walking distance, if any, is usually minor to moder-
ate, and varies considerably between patients [117]. 
Also, no additional benefits of those drugs are known 
when combined with exercise therapy and treatment 
with statins. Consequently, in the ESC guidelines [1], 
class of recommendation/level of evidence I / A/C was 
assigned only to exercise therapy and treatment with 
statins (for revascularization, class of recommendation/ 
/level of evidence IIa / B/C was assigned); no formal 
recommendations were formulated for other drugs. 
Among those other drugs, cilostazol and naftidrofuryl 
were identified as potentially useful. For other phar-
macological agents, i.e. pentoxifylline, prostanoids, 
buflomedil, L-arginine and maidenhair tree (Ginkgo 
biloba), it was concluded that insufficient data from 
randomized, controlled clinical trials were available to 
recommend them to patients with intermittent claudi-
cation [119–122]. In the 2016 ACC/AHA guidelines [2], 
the use of cilostazol as an efficient drug improving the 
symptoms of LEAD and increasing the walking distance of 
patients with intermittent claudication was assigned class 
of recommendation/level of evidence I/A; naftidrofuryl 
was not included in the guidelines, as it is not available 
in the United States. The use of pentoxifylline was not 
recommended (class/level III/B). In the 2015 guide-
lines published by the Society of Vascular Surgery [3], 
cilostazol was recommended (class/level 2/A); if the drug 
is not tolerated or contraindicated, pentoxifylline was 
recommended as an alternative (class/level 2/B).
Cilostazol is a type III phosphodiesterase inhibitor 
registered for the treatment of intermittent claudi-
cation. Several clinical trials showed that cilostazol 
increased the MWD and PFWD as compared to placebo 
[123, 124]. A systematic review comparing cilostazol 
with naftidrofuryl and pentoxifylline revealed that 
cilostazol was slightly less efficient than naftidrofuryl 
but more efficient than pentoxifylline [118]. Due to its 
Table 10. Anticoagulation therapy for patients with lower extremity artery disease who require chronic oral anticoagulation
Recommendation Class  
of recommendation
Level (quality)  
of evidence
For patients with LEAD and atrial fibrillation, OACs:
— are recommended for patients with ≥ 2 score on CHA2DS2-VASc scale 
— should be recommended for all other patients
I A
BIIa
For patients with LEAD and indication for OACs (e.g. atrial fibrillation, prosthetic heart 
valve or venous thromboembolism), treatment only with OACs should be considered
IIa B
For patients with LEAD and indication for OACs after surgical revascularization,  
treatment only with OACs should be considered
IIa C
For patients with LEAD and indication for OACs after intravascular revascularization, 
SAPT (ASA or clopidogrel) combined with an oral anticoagulant for at least 1 month 
should be considered, if the bleeding risk is low compared to the risk of stent/bypass  
occlusion
IIa C
For patients with LEAD and indication for OACs after intravascular revascularization, 
treatment only with OACs should be considered, if the bleeding risk is low compared  
to the risk of stent/bypass occlusion
IIa C
A combination of OAC and SAPT (ASA or clopidogrel) for longer than 1 month may  
be considered for patients with a high risk of ischemia, or with another strong indication 
for long-term SAPTa
IIb C
ASA: acetylsalicylic acid; LEAD: lower extremity artery disease; OAC: oral anticoagulant; SAPT: single antiplatelet therapy
The CHA2DS2-VASc score is calculated as follows: congestive heart failure — 1 point, arterial hypertension — 1 point, age ≥ 75 — 2 points, diabetes — 1 point, 
stroke — 2 points, vascular disease — 1 point, age 65-74 — 1 point, female sex — 1 point
aDefined as prior stent thrombosis, acute limb ischemia during oral anticoagulation or concomitant coronary artery disease (recent acute coronary syndrome, status 
post-stenting of the last patent coronary artery, multi-vessel coronary artery disease with incomplete revascularization in diabetic patients) 
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Table 11. Drugs with confirmed or potential efficacy in treating intermittent claudication
Drug Characteristics and evidence of benefits
Drugs with confirmed clinical efficacy in treating intermittent claudication, recommended by international  
claudication [1, 2]
Cilostazol
(dosing: 100 mg BID)
Type III phosphodiesterase inhibitor which increases the volume of cyclic AMP, thus inhibiting the 
contraction of smooth muscles and platelet aggregation. It reduces the proliferation of smooth 
muscles, which might play a role for patients undergoing angioplasty, and stimulates angiogenesis. 
Cilostazol also affects the serum levels of lipids, reducing the triglyceride levels and increasing the 
HDL-C 
It is registered by the FDA for treatment of intermittent claudication and improves MWD and 
PFWD compared to placebo. It is also more efficient than pentoxifylline [118, 123, 124], but its 
effect may vary [118, 133]
Frequent side effects include headache, diarrhoea and other gastrointestinal disorders. Due to its 
mechanism of action, cilostazol can reduce arterial blood pressure and induce arrhythmia. In ran-
domized clinical trials, cilostazol reduced the incidence of restenosis but increased the incidence 
of hemorrhagic complications in patients who had undergone intravascular treatment [125]
Main contraindications include: congestive heart failure, hemorrhagic stroke/unstable angina/ 
/heart attack/coronary intervention in the previous 6 months, history of significant ventricular 
arrhythmia, simultaneous use of ≥ 2 other anticoagulants (antiplatelets or antithrombotics), sever 
renal impairment (CrCl ≤ 25 mL/min) 
For patients who are simultaneously taking strong CYP3A4 inhibitors (e.g. certain macrolide an-
tibiotics, azole antifungal agents, HIV protease inhibitors), or CYP2C19 inhibitors (e.g. omepra-
zole), it is recommended to reduce the dose by half (to 50 mg BID) 
Naftidrofuryl
(dosing: 200 mg TID)
Serotonin-2 receptor antagonist which reduces the aggregation of red blood cells and platelets
Not registered by FDA; available only in Europe, but currently not available in Poland
Systematic review and meta-analysis revealed that it increased MWD and PFWD [134].  
In the systematic review, naftidrofuryl showed slightly higher efficacy than cilostazol [118] 
Side effects: mainly gastrointestinal, such as nausea, vomiting, diarrhoea, flatulence, abdominal 
discomfort. Causes less adverse events than cilostazol
Statins Registered for use in reducing cardiovascular risk, with the restriction that they are not  
registered for the treatment of intermittent claudication. The statins’ effect on claudication  
is unknown; they might impact vascular tension or stimulate angiogenesis
Side effects: headache, gastrointestinal symptoms (abdominal pain, constipation, flatulence,  
diarrhoea), muscular pain or myositis, increased liver enzyme activity, rarely cholestatic hepatitis, 
rhabdomyolysis
A number of meta-analyses have shown that statins significantly improve the PFWD  
and maximum walking distance (MWD) [31, 117]. In the randomized CLEVER trial,  
conservative treatment, including the use of statins, did not significantly improve the  
walking efficiency or reduce the symptoms in patients with intermittent claudication,  
as compared to supervised exercise training or stenting [135] 
Drugs with potential, but insufficiently confirmed efficacy in treating intermittent claudication
Pentoxifylline A methylxanthine derivative, improving oxygenation by increasing the deformation of red blood 
cells. Pentoxifylline can inhibit platelet aggregation and affect blood coagulation, especially when 
combined with anticoagulants
It is registered by the FDA for treatment of intermittent claudication. Some studies have shown 
pentoxifylline to increase PFWD and MWD compared to placebo [136], but a systematic review 
revealed vastly discrepant results in terms of increasing the walking distance [137]. Its clinical  
application is thus limited due to the difficulty in identifying patients who would benefit from 
treatment [137]
The ESC and ACC/AHA guidelines [1, 2] do not recommend using pentoxifylline, while the 2015 
guidelines of the Society of Vascular Surgery [3] recommend using pentoxifylline if cilostazol is 
not tolerated or contraindicated. Given the unavailability of naftidrofuryl in Poland, it seems that 
pentoxifylline may be sometimes considered as an alternative drug for improving the walking 
performance if cilostazol cannot be used and other methods (quitting smoking, exercise therapy, 
statins, revascularization) fail to improve the patient’s condition or cannot be used
cd.Æ
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Table 11 (cd).  Drugs with confirmed or potential efficacy in treating intermittent claudication
Lek Charakterystyka i dowody korzyści
Drugs with potential, but insufficiently confirmed efficacy in treating intermittent claudication
Antiplatelet drugs A systematic review revealed that antiplatelet therapy significantly increased PFWD compared 
to placebo [138], but the improvement of the walking distance was achieved mainly for older 
antiplatelet drugs, such as ticlopidine, while no evidence of the beneficial effect on LEAD was 
achieved for acetylsalicylic acid or clopidogrel. In one small trial, the combination of acetylsalicylic 
acid and dipyridamole increased PFWD and resting blood flow in the limbs of patients suffering 
from intermittent claudication [139]
L-carnitine and propionyl-
L-carnitine
Improve energy metabolism in ischemic muscles. Both propionyl-L-carnitine and L-carnitine were 
studied in clinical trials, showing a slight increase of PFWD and MWD compared to placebo, but 
finding no benefits compared to walking training [140–144]
L-arginine The drug has an indirect vasodilatory effect on the smooth muscles of the vessels. Administered 
intravenously, L-arginine increased MWD compared to placebo, however, no improvement was 
found in a 6-month study with an oral preparation [145, 146]
Prostanoids (prostaglan-
dins E1 and I2)
Prostanoids have a vasodilatory and antiplatelet effect. Prostaglandin E1 increased MWD  
compared to placebo [119, 147]; however, in the trials with beraprost (prostacyclin analogue), 
inconsistent results were obtained [148, 149]
Angiotensin-converting-
enzyme inhibitors (ACEI)
May be preferable for treatment of patients with PAD and arterial hypertension due to their  
vasodilatory effect and improvement of endothelial function, as well as the confirmed reduction  
of cardiovascular risk in patients with PAD through the renin-angiotensin system inhibitors
A randomized clinical trial showed that ACEI increased the walking distance in patients with  
intermittent claudication [67]
The results of trials using ACE inhibitors are controversial, since of the six trials with ACE  
inhibitors compared to placebo which was included in the meta-analysis in 2013 [68],  
an improvement in the walking distance was observed in three trials with ramipril, two of which 
were subsequently retracted due to unreliable data [69], while three trials with other ACE  
inhibitors (captopril, cilazapril, perindopril), no benefits were achieved. In the new meta-analysis, 
which included only the four trials remaining after the two studies on ramipril had been retracted, 
no improvement of the walking distance was found [70]
Verapamil Calcium antagonist which does not belong to dihydropyridine derivatives. A randomized clinical 
trial showed that verapamil extended the walking distance in patients with LEAD [66]
Maidenhair tree  
(Gingko biloba)
The mechanism of action of the maidenhair tree has not been fully explaining, but is likely an 
antioxidant and anticoagulant, inhibiting vascular injuries. A meta-analysis of 11 clinical trials only 
showed a trend towards the improvement of MWD [150]
Sulodexide A substance with a broad spectrum of effects (anticoagulant, profibrinolytic, anti-inflammatory, 
inhibiting fibrosis and protecting vascular endothelial cells)
The major international guidelines [1–3] do not list sulodexide among the drugs which are  
potentially useful in treating intermittent claudication, but in a randomized, double-blinded, placebo-
controlled SUAVIS clinical trial, an improvement of MWD and PFWD was shown at 6 months of 
treatment. The results of treatment in patients with and without diabetes were similar [120]
Padma 28 Padma 28 is a traditional Tibetan medicine containing 22 herbal ingredients. The review of trials  
in the Cochrane database yielded some data indicating an improvement of the walking distance,  
at least in short-term trials [151]. Long-term treatment effects are unknown. The available data 
have limited methodological value and the clinical significance of the observed walking  
performance improvement is questionable
All abbreviations in the text
antiplatelet action which increases the bleeding risk, 
care must be taken when combining cilostazol with 
other antiplatelets and anticoagulants, and also when 
using the drug in patients with other bleeding risk fac-
tors (e.g. active ulcer or improperly controlled arterial 
hypertension). In randomized clinical trials, cilostazol 
reduced the incidence of restenosis but increased the 
incidence of hemorrhagic complications in patients 
who had undergone intravascular treatment [125]. 
Frequent side effects include headache, diarrhoea and 
other gastrointestinal disorders. Due to its mechanism 
of action, cilostazol can reduce arterial blood pressure 
and induce arrhythmia. Main contraindications include 
congestive heart failure, history of significant ventricular 
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arrhythmia and simultaneous use of ≥ 2 other antico-
agulants (antiplatelets or antithrombotics). 
The treatment methods, for which no clinical benefits 
in terms of improving claudication and which are not 
recommended, include antithrombotic agents (warfa-
rin and low molecular weight heparin) [126], hormone 
replacement therapy [127, 128], garlic [129], vitamin E 
supplementation [130] and chelation therapy [131, 132].
Drugs with confirmed or potential clinical efficacy in 
treating intermittent claudication are listed in Table 11. 
The recommendations on the use of drugs improving 
the walking distance are listed in Tables 11, 12.
Table 12. Recommendations on drugs improving the walking distance
Recommendation Class of  
recommendation
Level (quality) 
of evidence
Cilostazol is recommended as a first-line symptomatic treatment drug to increase the 
pain-free walking distance in patients with LEAD and intermittent claudication provided 
that there are no contraindications for use
I A
Pentoxifylline may be considered as an alternative drug to increase the walking distance 
if cilostazol cannot be used The clinical efficacy of pentoxifylline in treating intermittent 
claudication has not been clearly confirmed and exhibit inter-individual variability
IIb B
Sulodexide may be considered in the treatment of intermittent claudication in patients 
with LEAD 
IIb B
The efficacy of other agents, such as L-arginine, L-carnitine/propionyl-L-carnitine,  
maidenhair tree (Gingko biloba) and prostanoids have not been unequivocally confirmed
GPS
Chelation therapy is inefficient in treating intermittent claudication and may have harmful 
side effects
III B
LEAD: lower extremity artery disease
Figure 4. Key information in the comprehensive approach to the treatment of patients with atherosclerotic lower extremity artery 
disease (modified from [152]) 
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6. Summary
The objective of the comprehensive treatment of 
LEAD is to reduce the risk of cardiovascular events 
and limb-related incidents and to improve the LEAD 
symptoms. The main treatment methods for patients 
with LEAD are provided in Figure 4. Following the 
review of the available evidence from scientific studies 
and formulation of the therapeutic recommendations, 
the Workgroup proposes the following 10 principles of 
conservative treatment of patients with LEAD:
1. Quitting smoking and using other non-pharmacolog-
ical methods to reduce cardiovascular risk (healthy 
diet, exercise).
2. Administering statins to patients with LEAD in order 
to achieve the target LDL-C level < 1.8 mmol/L (70 
mg/dL), or reduce it by ≥ 50%, if the initial LDL-C 
level is 1.8–3.5 mmol/L (70–135 mg/dL). 
3. Treating the concomitant arterial hypertension and 
diabetes.
4. Anticoagulation therapy for patients with symptomat-
ic LEAD or who have undergone revascularization.
5. In most patients, the basic treatment method is 
a single antiplatelet drug (ASA or clopidogrel, 
whereby clopidogrel may be preferable).
6. A promising new treatment strategy, providing 
an alternative to single antiplatelet therapy, is the 
combined anticoagulation therapy with ASA and 
a small dose of rivaroxaban.
7. Dual antiplatelet therapy is applied mainly in the 
initial period (≥ 1 month) after intravascular revascu-
larization, and in patients with an indication for dual 
antiplatelet therapy arising from the concomitant 
coronary artery disease.
8. Oral anticoagulation is applied mainly in patients with 
separate indications for such therapy (such as atrial fibril-
lation with stroke risk factors), usually as monotherapy, 
i.e. without the antiplatelet therapy, or in combination 
with a single antiplatelet drug, provided that there are 
other indications (e.g. int he first month following the 
implantation of a stent in peripheral vessels).
9. The basic method of symptomatic treatment of 
intermittent claudication is exercise therapy, i.e. 
walking training.
10. Cilostazol is the drug of choice to supplement the 
treatment increasing the claudication distance.
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